

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Examination of Changes in Patient Characteristics and Hydroxychloroquine use based on U.S. Food and Drug Administration's Recommendation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042965
Article Type:	Original research
Date Submitted by the Author:	23-Jul-2020
Complete List of Authors:	Kim, Eun Ji; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Coppa, Kevin; Northwell Health Hirsch, Jamie; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Abrahams, Sara; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Johnson, Jennifer; Northwell Health Feinstein Institutes for Medical Research, Lesser, Martin; Northwell Health Feinstein Institutes for Medical Research, Biostatistics; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Davidson, Karina W.; Feinstein Institute for Medical Research, Research; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Conigliaro, Joseph; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research,
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Examination of Changes in Patient Characteristics and Hydroxychloroquine use**
4 **based on U.S. Food and Drug Administration's Recommendation**
5

6 Eun Ji Kim, MD, MS, MS^{1,2}
7 Kevin Coppa, BS³
8 Jamie S. Hirsch, MD, MA, MSB^{1,2,3}
9 Sara Abrahams, BS²
10 Jennifer C. Johnson MS, MA¹
11 Martin Lesser PhD^{1,2}
12 Karina W. Davidson, PhD, MASc^{1,2}
13 Joseph Conigliaro, MD, MPH^{1,2}
14
15

16
17 The Northwell COVID-19 Research Consortium: Stuart L. Cohen, MD^{1,2}; Charlotte
18 Kvasnovsky, MD, PhD, MPH²; Stephen C. Machnicki, MD FCCP²; Alex Makhnevich MD^{1,2};
19 Prashant Malhotra, MD^{1,2}; Lyndonna Marrast, MD, MPH^{1,2}; Ramanak Mitra, MD²; Ernesto P.
20 Molmenti, MD²; Sonali Narain, MBBS, MPH^{1,2}; M. Wasif Saif MD, MBBS^{1,2}; Sanjaya
21 Satapathy, MD²; Shalin Shah, MD²
22
23

24 ¹ Institute of Health Innovations and Outcome Research, Feinstein Institutes for Medical
25 Research, Northwell Health, Manhasset, New York

26 ² Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health,
27 Hempstead, New York

28 ³ Department of Information Services, Northwell Health, New Hyde Park, New York
29
30
31

32 Concept and design: EK, KC, JH, KD, ML, JC, SC, SM, AM, PM, LM, RM, EM, SN, WS, SS

33 Acquisition: KC, JH

34 Drafting of the manuscript: EK, KC, JC, SA

35 Critical revision of the manuscript for important intellectual content: all authors

36 Statistical analysis: KC, ML, CK

37 Obtained funding: KD

38 Administrative, technical or material support: KD, JC

39 Supervision: EK, ML, KD, JH, JC
40
41
42
43
44

45 Corresponding author: Joseph Conigliaro, MD, MPH
46 2001 Marcus Avenue S160
47 Lake Success, NY 11042
48 jconigliaro@northwell.edu
49

50 2,658 words

51 5 tables/figure
52
53
54
55
56
57
58
59
60

Abstract (299/300 words)

Objective: To examine the association between hydroxychloroquine use and clinical outcomes arising from changes in the U.S. Food and Drug Administration (FDA)'s recommendation and changes in patient characteristics in each period.

Design: A retrospective cross-sectional analysis.

Setting and Participants: We included hospitalized adult patients with confirmed COVID-19 infections from 12 Northwell Health acute care hospitals between March 1, 2020 and May 11, 2020. We categorized changes in the FDA recommendation as pre-FDA approval (March 1, 2020-March 27, 2020), FDA approval (March 28, 2020-April 23, 2020), and FDA warning (April 24, 2020-May 11, 2020). The hydroxychloroquine treated group received at least one dose within 48 hours of hospital admission.

Primary outcome: A composite of intubation and inpatient death.

Results: The percentages of patients who were treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%) FDA approval, and 176 (16.5%) FDA warning period (p-value<0.001). Using propensity score-matching, there was a higher rate of the composite outcome among patients treated with hydroxychloroquine (49/192, 25.5%) compared to no hydroxychloroquine (66/384, 17.2%) in the pre-FDA approval period (p-value=0.03) but not in the FDA-approval period (25.5% vs 22.6%, p=0.08) or the FDA warning (21.0% vs 15.1%, p=0.11) periods. Coincidentally, there was an increase in number of COVID-19 patients and disease severity during the FDA approval period (24.1% during FDA approval versus 21.4% during pre-FDA approval period). Hydroxychloroquine use was associated with increased odds of the composite outcome during the pre-FDA approval period (OR=1.65 [1.09-2.51]) but not

1
2
3 during the FDA approval (OR=1.17 [0.99-1.39]) and FDA warning (OR=1.50 [0.94-2.39])
4
5 periods.
6

7 **Conclusions:** There were concurrent changes in percentage of COVID-19 patients treated with
8 hydroxychloroquine and the number (and disease severity) of hospitalized patients with COVID-
9
10 19 infections. Adverse clinical outcomes were significantly associated with hydroxychloroquine
11
12 use only during pre-FDA approval period but not during FDA-approval and warning periods.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

- The percentages of patients who were treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%) FDA approval, and 176 (16.5%) FDA warning period (p-value<0.001).
- Using propensity score-matching, there was a higher rate of the composite outcome of intubation and inpatient mortality among patients treated with hydroxychloroquine compared to no hydroxychloroquine in the pre-FDA approval period but not in the FDA-approval period or the FDA warning periods.
- Hydroxychloroquine use was associated with increased odds of the composite outcome during the pre-FDA approval period but not during the FDA approval and FDA warning periods.

review only

Introduction

Coronavirus Disease 2019 (COVID-19), which causes severe acute respiratory syndrome, has spread globally. One consequence has been the unprecedented number of intensive care unit (ICU) admissions requiring mechanical ventilation. The mortality of patients on mechanical ventilation has been reported to be 60-80% with an overall hospital mortality of 20-25%.^{1,2} As of June 10, 2020, over 7.3 million people have been infected with COVID-19 and 410,000 deaths have been reported globally.³ Although multiple vaccines are in preparation or have begun clinical testing, data on safety and efficacy required to immunize the general public is currently unavailable and may be months to years away. Therefore, the need to identify medications that are associated with slowed COVID-19 progression or decreased mortality remains urgent.

Hydroxychloroquine, a medication commonly used to prevent malaria infection and treat autoimmune diseases, has been found to be effective in treating COVID-19 *in vitro*.⁴⁻⁹ Hydroxychloroquine is found to reduce the entry of coronavirus into a cell through interference with the terminal glycosylation of angiotensin-converting enzyme 2 receptor, which inhibits viral replication.^{4,6} Additionally, hydroxychloroquine has immunomodulatory activity, and may inhibit cytokine production and prevent the occurrence of cytokine storm.¹⁰ Early evidence suggests that hydroxychloroquine can serve as a potential treatment for COVID-19.¹¹⁻¹³ However, recent studies examining treatment of COVID-19 with hydroxychloroquine showed mixed results, with some studies showing no average benefit in outcomes, including intubation or inpatient mortality, but other studies showed worse outcomes.¹⁴⁻¹⁸

However, no study has accounted for how changes in recommendations for hydroxychloroquine by the United States Food and Drug Administration (FDA) affected outcomes of patients treated for COVID-19. On March 28, 2020, the FDA issued an Emergency

1
2
3 Use Authorization for hydroxychloroquine in the treatment of COVID-19 infection. During this
4
5 time, there was also an increased number of hospitalized patients with COVID-19, which may
6
7 have resulted in changes in hospital capacity and disease severity.³ Subsequently, on April 24,
8
9 2020, the FDA cautioned against using hydroxychloroquine for COVID-19 infection.¹⁹ These
10
11 changes in the recommendation of hydroxychloroquine as a treatment for COVID-19 infection
12
13 may have impacted whether patients were treated with hydroxychloroquine for COVID-19.
14
15 These two events occurring concurrently could affect the association of hydroxychloroquine with
16
17 COVID-19 outcomes. Therefore, we used data from one of the largest healthcare systems in the
18
19 United States and examined the association between hydroxychloroquine use and patients'
20
21 clinical outcomes based on changes in FDA recommendation.
22
23
24
25
26
27

28 **Methods**

29 *Setting*

30
31
32 We used data from Northwell Health, the largest academic healthcare system in New
33
34 York. Northwell Health serves approximately 11 million patients throughout Long Island, New
35
36 York City, and Westchester County and has 23 affiliated healthcare facilities, including 12 acute
37
38 care hospitals. The Institutional Review Board for the Feinstein Institutes for Medical Research
39
40 at Northwell Health approved this case series as minimal-risk research using data collected for
41
42 routine clinical practice and waived the requirement for informed consent.
43
44
45
46
47
48

49 *Data Source*

1
2
3 Data for this study was obtained from the enterprise's inpatient electronic health record
4 (EHR; Sunrise Clinical Manager, Allscripts, Chicago, IL), which covers 12 of Northwell
5
6 Health's hospitals.
7
8
9

10 11 12 *Study Population* 13

14
15 The study population included all adult patients (n=13,258), aged 18 years and older,
16 hospitalized at one of Northwell Health's 12 acute care hospitals between March 1, 2020 and
17 May 11, 2020 with a diagnosis of COVID-19 confirmed by a positive result on polymerase chain
18 reaction testing of a nasopharyngeal sample. For patients with multiple COVID-19 tests, they
19 were considered to have a confirmed COVID-19 infection if any of the repeated tests within the
20 same hospitalization returned positive. We excluded patients who died or were intubated within
21 one day of hospitalization because their clinical outcomes were likely predetermined by pre-
22 hospitalization factors. We also excluded patients who were discharged within one day of
23 admission. Patients who were admitted to the obstetrics service were excluded as all obstetrics
24 patients were screened for COVID-19 on their admission. For patients with multiple
25 hospitalizations for COVID-19, we used their first hospitalization with a confirmed diagnosis of
26 COVID-19. We excluded 3,249 patients who did not meet the inclusion and exclusion criteria.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 45 *Exposure* 46

47 Patients were identified as treated with hydroxychloroquine if they received at least one
48 dose within 48 hours of admission. The control group for this analysis consisted of patients who
49 were not treated with hydroxychloroquine within 48 hours of admission. Patients who did not
50 initially receive hydroxychloroquine within 48 hours but received the medication later in their
51
52
53
54
55
56
57
58
59
60

1
2
3 hospitalization were kept in the control group. We excluded COVID-19 patients who were
4 treated with azithromycin or a combination of hydroxychloroquine and azithromycin. We also
5 excluded patients who were intubated prior to getting their first dose of hydroxychloroquine
6 within 48 hours of admission.
7
8
9
10
11
12
13

14 *Outcomes*

15
16
17 The primary outcome of interest was a composite outcome of the earlier of time to
18 intubation or time to inpatient death. Time until composite event was censored at time of
19 discharge for patients who were discharged alive with no intubation during their hospitalization.
20
21 The rationale for the combined primary outcome was twofold: 1) many patients who deteriorated
22 clinically died without being intubated, often due to transition to palliative care; and 2)
23 hospitalization stays for intubated COVID-19 patients have been very long, and many intubated
24 COVID-19 patients at the time of the analyses may not ultimately survive. For a sensitivity
25 analysis, we used death as the outcome. We tracked all patients who were not discharged or died
26 until June 1, 2020.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 *Covariates*

41
42 We collected data on patients' demographic characteristics and comorbidities.
43
44 Demographic characteristics included age, sex, race/ethnicity, and health insurance (commercial,
45 Medicaid, Medicare, other, and no insurance). We used patient-reported race and ethnicity
46 information and categorized patients into one of five racial/ethnic groups: White, Black, Asian,
47 Other/Multiracial, and Unknown/Declined. We also identified a subgroup of patients who
48 received immunomodulatory medications, including steroids (prednisone or
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 methylprednisolone), sarilumab, tocilizumab, anakinra, or colchicine, and included this
4
5 information as a covariate. We identified the presence of the following comorbidities by
6
7 *International Statistical Classification of Disease and Related Health Problems, Tenth Revision*
8
9 *(ICD-10)* coding: cancer, coronary artery disease, hypertension, asthma, chronic obstructive
10
11 pulmonary disease, diabetes, chronic liver disease, chronic kidney disease, and end stage renal
12
13 disease. We calculated the Charlson Comorbidity Index, which is an index that predicts the 10-
14
15 year survival of patients with multiple comorbidities, as a measure of total comorbidity burden.²⁰
16
17 The only covariate with missing data was BMI, and we categorized the BMI group as not obese
18
19 (BMI less than 30kg/m²), obese (BMI greater than or equal to 30kg/m²), and missing BMI.
20
21

22
23
24 We categorized changes in FDA recommendation for hydroxychloroquine, into three
25
26 time periods: 1) pre-FDA approval (March 1-March 27, 2020); 2) FDA approval (March 28-
27
28 April 23, 2020); and 3) FDA warning (April 24-May 11, 2020).
29
30

31 32 33 *Statistical analysis*

34
35 All analyses were performed using version 3.5.2 of the R Programming Language (R
36
37 Project for Statistical Computing, R Foundation, Vienna, Austria). We first performed chi-square
38
39 and 2-sample t-tests to compare patient characteristics treated with hydroxychloroquine to no
40
41 hydroxychloroquine (control).
42
43

44
45 We used propensity-score matching methods, 1:2 for the pre-FDA approval and the FDA
46
47 warning periods and 1:1 for the FDA approval period, using the smaller group as a reference,
48
49 within each period and applied the nearest-neighbor method to create a matched control sample.
50
51 The propensity-score matching was performed within each period so that patients admitted
52
53
54
55
56
57
58
59
60

1
2
3 within the FDA approval period were not matched to patients in the pre-FDA approval or FDA
4 warning periods, so as not to confound the effect of different FDA recommendations.
5
6

7 We then took the following approach to conduct the analysis. We first performed logistic
8 regressions to compare the propensity score-matched hydroxychloroquine group to the control
9 group. For a time-to-event analysis, we used the Kaplan-Meier survival estimate and log-rank
10 test. We examined the Kaplan-Meier survival curves for the treatment group compared to the
11 control group, separated by the different FDA recommendation periods. If a patient was
12 discharged alive without intubation, data was censored at the time of hospital discharge. Then,
13 we used Cox proportional-hazard regression models to estimate the association between the
14 propensity-matched treatment group to the control group with respect to end point free survival
15 time. We used the Schoenfeld residuals to test the proportional hazard assumption in the Cox
16 model.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Results**

34 *Characteristics of the cohort*

35 From a cohort of 10,009 patients, 3,270 (32.7%) were treated with hydroxychloroquine,
36 2,640 (26.4%) with neither hydroxychloroquine nor azithromycin, 1,289 (12.9%) with
37 azithromycin only, and 2,810 (28.1%) with the combination hydroxychloroquine and
38 azithromycin. There were differences in the number of patients treated with or without
39 hydroxychloroquine and/or azithromycin by admission period (Figure 1).
40
41
42
43
44
45
46
47
48

49 We found significant differences in the use of hydroxychloroquine and patient
50 characteristics based on changes to FDA recommendation. Number and percentages of patients
51 treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%)
52
53
54
55
56
57
58
59
60

1
2
3 during FDA approval, and 176 (16.5%) during the FDA warning period (p-value<0.001). There
4
5 was a significant increase in number of patients during the FDA approval period (March 28-
6
7 April 23). During the pre-FDA approval period, there were 2,202 patients admitted with COVID-
8
9 19 infection, but in the following periods, the number of patients admitted with COVID-19
10
11 infections was 6,741 (FDA approval period) and 1,066 (FDA warning period). Throughout the
12
13 study, and independent of FDA periods, there were differences in sociodemographic and clinical
14
15 characteristics between the treatment group compared to the control group (Table 1). Higher
16
17 percentage of patients who were younger (36.8% vs 32.5% were less than 60 years old), male
18
19 (59.9% vs 53.4%), and had commercial insurance (31.0% vs 24.2%) were treated with
20
21 hydroxychloroquine (p-values<0.001). Presence of comorbidity was associated with
22
23 hydroxychloroquine use (all p-values<0.05), except for asthma and diabetes, and chronic kidney
24
25 disease.
26
27
28
29

30
31 Hydroxychloroquine groups (13.4%) had higher rates of intubation compared to the
32
33 control group (7.0%) (p-value<0.001). Inpatient mortality was 20.2% for hydroxychloroquine
34
35 versus 18.3% for no hydroxychloroquine treatment (p-value=0.01). A significantly higher
36
37 percentage of patients treated with hydroxychloroquine (23.4%) reached the composite outcome
38
39 compared to the control group (20.4%) (p-value=0.007). A higher percentage of patients on
40
41 hydroxychloroquine (52.8%) were treated concurrently with immunomodulatory medications
42
43 compared to the control group (24.7%) (p-value<0.001).
44
45

46
47 After propensity-score matching within each time period, sociodemographic
48
49 characteristics and comorbidity were similar between hydroxychloroquine and no
50
51 hydroxychloroquine group (Table 2). There were 576 patients in the pre-FDA approval period,
52
53 2812 patients in the FDA approval period, and 528 FDA warning period. There was a higher
54
55
56
57
58
59

1
2
3 composite outcome among patients treated with hydroxychloroquine (25.5%) compared to no
4 hydroxychloroquine (17.2%) during the pre-FDA approval period (p-value=0.03) but no
5
6 difference in the number of composite outcomes between hydroxychloroquine and no
7
8 hydroxychloroquine groups in the FDA-approval period (25.5%, vs 22.6% p=0.08) or the FDA
9
10 warning period (21.0 vs 15.1% %, p=0.11) (Table 3). In multivariable logistic regression
11
12 analysis, hydroxychloroquine use was associated with increased odds of the composite outcome
13
14 during the pre-FDA approval period (OR=1.65 [1.09-2.51]) but there was no association during
15
16 the FDA approval (OR=1.17 [0.99-1.39]) as well as the FDA warning period (OR=1.50 [0.94-
17
18 2.39]).
19
20
21
22
23
24
25

26 *Time-to event analysis*

27
28 Figure 2 shows the Kaplan-Meier curves of freedom from the composite end point of
29
30 intubation and inpatient mortality during the pre-FDA approval period, the FDA approval period,
31
32 or the FDA warning period. The cox proportional-hazard regression models showed
33
34 hydroxychloroquine use was associated with the composite outcome of intubation and inpatient
35
36 mortality during the pre-FDA approval (hazard ratio=1.70 [1.17-2.48]) and the FDA warning
37
38 (hazard ratio=1.53 [1.00-2.34]) period but not during the FDA approval period (hazard
39
40 ratio=1.03 [0.88-1.20]) (Table 3).
41
42
43
44
45
46
47
48

49 **Discussion**

50
51 In our study, while there were changes in percentage of COVID-19 patients treated with
52
53 hydroxychloroquine with FDA recommendations, there was also a fluctuation of the number of
54
55
56
57
58
59
60

1
2
3 hospitalized patients with COVID-19 infections during the FDA approval period.

4
5 Hydroxychloroquine treatment was associated with increased composite outcome of intubation
6
7 or death during pre-FDA approval period but not during FDA approval or FDA warning period.

8
9
10 The overall association of hydroxychloroquine treatment among COVID-19 patients in our
11
12 cohort was similar to previous studies showing no association between the treatment and primary
13
14 end point of intubation or death.^{14,15}

15
16
17 Although not captured in our study, hospitals during the FDA approval period had to
18
19 manage sudden increases in critically ill patients. As hospitals were reaching their maximum
20
21 capacity, coordinated efforts were made to ensure that there were adequate ventilators for
22
23 patients with pulmonary complications, goals of care discussions for patients with poor
24
25 prognosis, and an increase in ambulatory management to ensure medical care for all patients.²¹⁻²³
26
27 Therefore, patients who were admitted during this period may have had more severe disease,
28
29 including hypoxia, requiring ventilators. This hypothesis is also consistent with the higher
30
31 proportions of patients experiencing the composite outcome during this period. There was also
32
33 an increased use of immunomodulators, which were more often used for patients with more
34
35 complications, including acute respiratory distress syndrome, acute kidney injury, thrombosis,
36
37 etc.^{1,24,25} Therefore, regardless of whether they were being treated with hydroxychloroquine or
38
39 not, patients admitted during the FDA approval period had overall worse outcomes compared to
40
41 patients admitted during other periods. Because of such differences in patient disease severity
42
43 and hospital settings, we used propensity-score matching of patients within each period so that
44
45 the patients treated in the pre-FDA approval or FDA warning periods were not matched with
46
47 patients treated in the FDA approval period.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The lack of efficacy of hydroxychloroquine could be attributed to the severity of disease
4 among patients receiving medication. The hypothesized mechanism of action of
5 hydroxychloroquine is that it prevents the virus from entering cells and blocks viral replication.⁴
6
7
8
9
10 ⁶ These patients were hospitalized because of a severe course of disease, and therefore it is likely
11 that viral replication was already high when hydroxychloroquine was administered. This may be
12 particularly true for patients who were hospitalized during the FDA approved period because
13 hospitals had a high number of COVID-19 patients requiring inpatient care. Also,
14 hydroxychloroquine may have been administered to more severely ill patients and subsequently
15 was associated with higher risk of intubation and/or inpatient mortality. We addressed this by
16 propensity-score matching patients treated with hydroxychloroquine to no hydroxychloroquine.
17 Of note, higher doses of hydroxychloroquine have been associated with adverse intermediate
18 outcomes, including QTc prolongation, in another study.²⁶
19
20
21
22
23
24
25
26
27
28
29
30

31 This study has several limitations. Due to the observational study design, this study does
32 not establish causal relationships between medication treatment and outcomes. Also, this study is
33 limited to the inpatient setting, therefore the study findings are not generalizable to outpatient or
34 community settings. Though we did attempt to adjust for covariates, it is possible that the
35 severity of illness and precise timing of treatment also may have influenced the association of
36 these medications with the outcome. There might be a subset of patients who were taking
37 hydroxychloroquine prescribed by their ambulatory providers prior to their hospitalization. It is
38 possible that some patients in the no hydroxychloroquine group were taking the medications or
39 already had completed their 5-day course prior to hospitalization. There was a subset of patients
40 in the control group who were treated with hydroxychloroquine or azithromycin after 48 hours
41 because of their disease progression. The changes in the FDA recommendations probably also
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 caused some patients admitted during the pre-FDA approval period to be treated with
4 hydroxychloroquine during their prolonged hospitalizations. This could result in bias toward the
5 null, that is, erroneously concluding no difference between hydroxychloroquine and control
6 (Type II error).
7
8
9
10
11

12 In addition to changes in the FDA recommendation, this study addresses changes in case
13 mix due to changes in number of COVID-19 patients being hospitalized. Regardless of FDA
14 recommendation for the drug, we did not observe any beneficial association of
15 hydroxychloroquine use throughout the study period. This study suggests that
16 hydroxychloroquine may not alter the clinical course among patients with COVID-19 infections
17 in the inpatient setting where patients have more severe disease. However, it is unclear whether
18 hydroxychloroquine treatment can be used in patients with milder symptoms and possibly in an
19 outpatient setting. On June 15, 2020, the FDA revoked the Emergency Use Authorization for
20 hydroxychloroquine in the treatment of COVID-19 infection and this will further decrease the
21 number of COVID-19 patients being treated with hydroxychloroquine.²⁷ These study results
22 should not be used as guidance on whether or not to treat COVID-19 patients with or without
23 hydroxychloroquine due to its observational design.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Data Availability Statement**

43
44 The data that support the findings of this study are available on request from
45 COVID19@northwell.edu. The data are not publicly available due to restrictions as it could
46 compromise the privacy of research participants.
47
48
49
50
51

52 **Conflict of Interest Disclosures**

1
2
3 The authors report no real or apparent conflicts of interest.
4
5
6

7
8 **Funding/Support**
9

10 This work was supported by grants R24AG064191 from the National Institute on Aging of the
11 National Institutes of Health and R01LM012836 from the National Library of Medicine of the
12 National Institutes of Health.
13
14
15
16

17
18
19 **Role of the Funder/Sponsor**
20

21 The funders had no role in the design and conduct of the study; collection, management,
22 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
23 decision to submit the manuscript for publication. The views expressed in this paper are those of
24 the authors and do not represent the views of the National Institutes of Health, the United States
25 Department of Health and Human Services, or any other government entity.
26
27
28
29
30
31
32
33
34

35 **Patient and Public Involvement**
36

37 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
38 plans of our research
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020.
3. The Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. 2020; <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Accessed June 10, 2020.
4. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020.
5. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-271.
6. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology.* 2005;2:69.
7. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* 2020;6:16.
8. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020;145:104228.
9. Grassin-Delyle S, Salvator H, Brollo M, et al. Chloroquine inhibits the release of inflammatory cytokines by human lung explants. *Clin Infect Dis.* 2020.
10. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol.* 2020;16(3):155-166.
11. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020:105949.
12. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends.* 2020;14(1):72-73.
13. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv.* 2020.
14. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020.
15. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA.* 2020.
16. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ.* 2020;369:m1849.

17. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect.* 2020;50(4):384.
18. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv.* 2020.
19. Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. <https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use>. Accessed May 15, 2020.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
21. Curtis JR, Kross EK, Stapleton RD. The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019 (COVID-19). *JAMA.* 2020.
22. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *BMJ.* 2020;368:m1182.
23. White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic. *JAMA.* 2020.
24. Hirsch JS, Ng JH, Ross DW, et al. Acute Kidney Injury in Patients Hospitalized with Covid-19. *Kidney Int.* 2020.
25. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood.* 2020;135(23):2033-2040.
26. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open.* 2020;3(4):e208857.
27. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. June 15, 2020; <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and>. Accessed June 20, 2020.

Table 1. Patient characteristics before propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	All (n=10,009)	HCQ (n=3,270)	No HCQ (n=2,640)	P-value*
Sociodemographic characteristics				
Age at admission, mean (SD)	64.99 (16.35)	64.29 (15.58)	66.87 (17.73)	<0.001
Age group				<0.001
18-49	1747 (17.5)	558 (17.1)	434 (16.4)	
50-59	1863 (18.6)	645 (19.7)	425 (16.1)	
60-69	2277 (22.7)	816 (25.0)	530 (20.1)	
70-79	2046 (20.4)	671 (20.5)	518 (19.6)	
80+	2076 (20.7)	580 (17.7)	733 (27.8)	
Male	5847 (58.4)	1959 (59.9)	1411 (53.4)	<0.001
Race				<0.001
White	3923 (39.2)	1151 (35.2)	1182 (44.8)	
Black	2104 (21.0)	632 (19.3)	581 (22.0)	
Asian	849 (8.5)	327 (10.0)	236 (8.9)	
Other/Multiracial	2648 (26.5)	958 (29.3)	540 (20.5)	
Unknown	485 (4.8)	202 (6.2)	101 (3.8)	
Health insurance				<0.001
Commercial	2947 (29.4)	1013 (31.0)	638 (24.2)	
Medicaid	2041 (20.4)	712 (21.8)	488 (18.5)	
Medicare	4754 (47.5)	1431 (43.8)	1453 (55.0)	
Other	133 (1.3)	46 (1.4)	45 (1.7)	
No insurance	134 (1.3)	68 (2.1)	16 (0.6)	
Comorbidity				
Cancer	832 (8.3)	238 (7.3)	278 (10.5)	<0.001
Coronary artery disease	1339 (13.4)	399 (12.2)	429 (16.2)	<0.001
Hypertension	6073 (60.7)	1973 (60.3)	1673 (63.4)	0.02
Peripheral artery/vascular disease	282 (2.8)	81 (2.5)	100 (3.8)	0.005
Asthma	842 (8.4)	271 (8.3)	198 (7.5)	0.29
Chronic obstructive pulmonary disease	639 (6.4)	168 (5.1)	174 (6.6)	0.02
Diabetes	3624 (36.2)	1233 (37.7)	945 (35.8)	0.14
Chronic liver disease	298 (3.0)	74 (2.3)	110 (4.2)	<0.001
Chronic kidney disease	507 (5.1)	155 (4.7)	152 (5.8)	0.09
End stage renal disease	461 (4.6)	144 (4.4)	168 (6.4)	0.001
Charlson Comorbidity Index, mean SD	4.89 (3.58)	4.56 (3.38)	5.74 (3.77)	<0.001
Obesity				<0.001
Obese	2810 (28.1)	1001 (30.6)	570 (21.6)	
Not obese	4632 (46.3)	1483 (45.4)	1296 (49.1)	
Missing BMI	2567 (25.6)	786 (24.0)	774 (29.3)	
BMI, mean (SD)	29.23 (7.06)	29.66 (7.04)	28.13 (7.14)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Clinical outcomes**

Admission week				<0.001
Pre-FDA approval	2202 (22.0)	192 (5.9)	496 (18.8)	
FDA approval	6741 (67.3)	2902 (88.7)	1406 (53.3)	
FDA warning	1066 (10.7)	176 (5.4)	738 (28.0)	
Length of stay, mean (SD)	9.51 (9.60)	9.56 (9.14)	8.80 (9.27)	0.001
Immunomodulator use	4183 (41.8)	1727 (52.8)	651 (24.7)	<0.001
ICU stay	1985 (19.8)	583 (17.8)	426 (16.1)	0.09
Mechanical ventilation	1314 (13.1)	437 (13.4)	186 (7.0)	<0.001
Inpatient mortality	1983 (19.8)	660 (20.2)	482 (18.3)	0.01
Composite Outcome	2413 (24.1)	764 (23.4)	538 (20.4)	0.007

* Comparing hydroxychloroquine group to no treatment group

Table 2. Patient characteristics after propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	Pre-FDA approval				FDA approval				FDA warning			
	HCQ (n=192)	No HCQ (n=384)	P- value*	SMD	HCQ (n=1406)	No HCQ (n=1406)	P- value*	SMD	HCQ (n=176)	No HCQ (n=352)	P- value*	SMD
Sociodemographic characteristics												
Age at admission, mean (SD)	61.1 (15.8)	62.8 (17.2)	0.26	0.101	67.8 (15.8)	67.3 (17.6)	0.42	0.03	66.2 (16.2)	66.3 (17.6)	0.94	0.007
Male	109 (56.8)	218 (56.8)	1.00	0.01	740 (52.6)	765 (54.4)	0.36	0.036	92 (52.3)	194 (55.1)	0.60	0.057
Race			0.68	0.134			1.00	0.013			0.99	0.05
White	91 (47.4)	180 (46.9)			610 (43.4)	612 (43.5)			65 (36.9)	136 (38.6)		
Black	35 (18.2)	86 (22.4)			306 (21.8)	302 (21.5)			37 (21.0)	69 (19.6)		
Asian	17 (8.9)	37 (9.6)			143 (10.2)	143 (10.2)			12 (6.8)	25 (7.1)		
Other/Multiracial	44 (22.9)	72 (18.8)			297 (21.1)	296 (21.1)			53 (30.1)	106 (30.1)		
Unknown	5 (2.6)	9 (2.3)			50 (3.6)	53 (3.8)			9 (5.1)	16 (4.5)		
Health insurance			0.02	0.257			0.90	0.039			1.00	0.036
Commercial	91 (47.4)	134 (34.9)			306 (21.8)	321 (22.8)			44 (25.0)	92 (26.1)		
Medicaid	30 (15.6)	72 (18.8)			246 (17.5)	249 (17.7)			31 (17.6)	62 (17.6)		
Medicare	71 (37.0)	178 (46.4)			819 (58.3)	805 (57.3)			92 (52.3)	182 (51.7)		
Other	0 (0.0)	0 (0.0)			27 (1.9)	22 (1.6)			6 (3.4)	11 (3.1)		
No insurance	0 (0.0)	0 (0.0)			8 (0.6)	9 (0.6)			3 (1.7)	5 (1.4)		
Comorbidity												
Cancer	10 (5.2)	25 (6.5)	0.67	0.055	134 (9.5)	151 (10.7)	0.32	0.04	16 (9.1)	30 (8.5)	0.96	0.02
Coronary artery disease	23 (12.0)	56 (14.6)	0.47	0.077	218 (15.5)	222 (15.8)	0.88	0.008	27 (15.3)	53 (15.1)	1.00	0.008
Hypertension	109 (56.8)	237 (61.7)	0.29	0.101	915 (65.1)	884 (62.9)	0.24	0.046	107 (60.8)	205 (58.2)	0.64	0.052
Peripheral artery/vascular disease	7 (3.6)	13 (3.4)	1.00	0.014	48 (3.4)	42 (3.0)	0.59	0.024	6 (3.4)	6 (1.7)	0.35	0.108
Asthma	24 (12.5)	35 (9.1)	0.26	0.109	88 (6.3)	100 (7.1)	0.41	0.034	17 (9.7)	32 (9.1)	0.96	0.019
Chronic obstructive pulmonary disease	9 (4.7)	23 (6.0)	0.65	0.058	83 (5.9)	87 (6.2)	0.81	0.012	14 (8.0)	29 (8.2)	1.00	0.01
Diabetes	70 (36.5)	138 (35.9)	0.98	0.011	515 (36.6)	508 (36.1)	0.81	0.01	68 (38.6)	131 (37.2)	0.82	0.029
Chronic liver disease	7 (3.6)	15 (3.9)	1.00	0.014	47 (3.3)	56 (4.0)	0.42	0.034	7 (4.0)	19 (5.4)	0.62	0.067
Chronic kidney disease	11 (5.7)	25 (6.5)	0.86	0.033	84 (6.0)	80 (5.7)	0.81	0.012	8 (4.5)	17 (4.8)	1.00	0.013

1													
2													
3	End stage renal												<0.0
4	disease	12 (6.2)	27 (7.0)	0.86	0.031	99 (7.0)	101 (7.2)	0.94	0.006	4 (2.3)	8 (2.3)	1.00	01
5	Charlson												
6	Comorbidity Index,									5.03			
7	mean SD	4.23 (3.19)	4.73 (3.32)	0.09	0.152	5.72 (3.75)	5.69 (3.73)	0.84	0.008	(3.23)	5.01 (3.42)	0.96	0.005
8	Obesity			0.08	0.198			0.84	0.022			0.96	0.027
9	Obese	76 (39.6)	116 (30.2)			289 (20.6)	292 (20.8)			50 (28.4)	98 (27.8)		
10	Not obese	69 (35.9)	160 (41.7)			678 (48.2)	663 (47.2)			84 (47.7)	166 (47.2)		
11	Missing BMI	47 (24.5)	108 (28.1)			439 (31.2)	451 (32.1)			42 (23.9)	88 (25.0)		
12	Clinical outcomes												
13	Length of stay, mean	10.88	10.48					<0.00		8.67			
14	(SD)	(11.20)	(11.79)	0.70	0.035	9.29 (8.66)	7.75 (7.82)	1	0.187	(7.55)	8.28 (7.40)	0.57	0.053
15	Mechanical							<0.00					
16	ventilation	33 (17.2)	29 (7.6)	0.001	0.296	168 (11.9)	85 (6.0)	1	0.207	26 (14.8)	25 (7.1)	0.008	0.248
17	Inpatient mortality	31 (16.1)	55 (14.3)	0.32	0.272	318 (22.6)	294 (20.9)	0.32	0.086	32 (18.2)	46 (13.1)	1.00	0.079
18	Composite Outcome	49 (25.5)	66 (17.2)	0.03	0.204	359 (25.5)	318 (22.6)	0.08	0.068	37 (21.0)	53 (15.1)	0.11	0.156

* Comparing hydroxychloroquine group to no treatment group

SMD=Standardized mean difference

Table 3. Association between hydroxychloroquine use and the composite end point in the crude analysis and propensity-score matched analysis

Analysis	Results	P-value*
Composite outcome among patients at risk, n (%)		
Before propensity score matching		
All periods		
Overall	2080/10009 (23.9)	-
Hydroxychloroquine	764/3270 (23.4)	0.007
No HCQ	538/2640 (20.4)	
After propensity score matching		
Pre-FDA approval		
Hydroxychloroquine	49/192 (25.5)	0.03
No HCQ	66/384 (17.2)	
FDA approval		
Hydroxychloroquine	359/1406 (25.5)	0.08
No HCQ	318/1406 (22.6)	
FDA warning		
Hydroxychloroquine	37/176 (21.0)	0.11
No HCQ	53/352 (15.1)	
Multivariable analysis - odds ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.65 [1.09-2.51]	0.02
FDA approval (reference: no HCQ)	1.17 [0.99-1.39]	0.07
FDA warning (reference: no HCQ)	1.50 [0.94-2.39]	0.09
Propensity-score matched analyses-hazard ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.70 [1.17-2.48]	0.005
FDA approval (reference: no HCQ)	1.03 [0.88-1.20]	0.72
FDA warning (reference: no HCQ)	1.53 [1.00-2.34]	0.05

* Comparing hydroxychloroquine group to no treatment group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure 1. Number of patients treated with different medications






Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or inpatient mortality by different time period

a. Pre-FDA approval



b. FDA approval




		Number at risk				
Txt Group		0	7	14	21	28
	No Txt		1406	498	148	60
HCQ		1406	589	158	54	24

Time



c. FDA warning



Number at risk

Txt Group	0	7	14	21	28
No Txt	352	124	51	25	5
HCQ	176	64	16	6	1

Time

BMJ Open

Examination of patient characteristics and hydroxychloroquine use based on U.S. Food and Drug Administration's recommendation: a cross-sectional analysis in New York

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042965.R1
Article Type:	Original research
Date Submitted by the Author:	17-Nov-2020
Complete List of Authors:	Kim, Eun Ji; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Coppa, Kevin; Northwell Health Hirsch, Jamie; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Abrahams, Sara; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Johnson, Jennifer; Northwell Health Feinstein Institutes for Medical Research, Lesser, Martin; Northwell Health Feinstein Institutes for Medical Research, Biostatistics; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Davidson, Karina W.; Feinstein Institute for Medical Research, Research; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Conigliaro, Joseph; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research,
Primary Subject Heading:	Global health
Secondary Subject Heading:	Epidemiology, Health policy, Health services research, Infectious diseases, Medical management
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Examination of patient characteristics and hydroxychloroquine use based on U.S.**
4 **Food and Drug Administration's recommendation: a cross-sectional analysis in New York**
5

6 Eun Ji Kim, MD, MS, MS^{1,2}
7 Kevin Coppa, BS³
8 Jamie S. Hirsch, MD, MA, MSB^{1,2,3}
9 Sara Abrahams, BS²
10 Jennifer C. Johnson MS, MA¹
11 Martin Lesser PhD^{1,2}
12 Karina W. Davidson, PhD, MASc^{1,2}
13 Joseph Conigliaro, MD, MPH^{1,2}
14
15

16
17 The Northwell COVID-19 Research Consortium: Stuart L. Cohen, MD^{1,2}; Charlotte
18 Kvasnovsky, MD, PhD, MPH²; Stephen C. Machnicki, MD FCCP²; Alex Makhnevich MD^{1,2};
19 Prashant Malhotra, MD^{1,2}; Lyndonna Marrast, MD, MPH^{1,2}; Ramanak Mitra, MD²; Ernesto P.
20 Molmenti, MD²; Sonali Narain, MBBS, MPH^{1,2}; M. Wasif Saif MD, MBBS^{1,2}; Sanjaya
21 Satapathy, MD²; Shalin Shah, MD²
22
23

24 ¹ Institute of Health Innovations and Outcome Research, Feinstein Institutes for Medical
25 Research, Northwell Health, Manhasset, New York

26 ² Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health,
27 Hempstead, New York

28 ³ Department of Information Services, Northwell Health, New Hyde Park, New York
29
30
31

32 Contributorship Statement

33 Concept and design: EK, KC, JH, KD, ML, JC, SC, SM, AM, PM, LM, RM, EM, SN, WS, SS

34 Acquisition: KC, JH

35 Drafting of the manuscript: EK, KC, JC, SA, JJ

36 Critical revision of the manuscript for important intellectual content: all authors

37 Statistical analysis: KC, ML, CK

38 Obtained funding: KD

39 Administrative, technical or material support: KD, JC

40 Supervision: EK, ML, KD, JH, JC
41
42
43
44
45

46 Corresponding author: Joseph Conigliaro, MD, MPH

47 2001 Marcus Avenue S160

48 Lake Success, NY 11042

49 jconigliaro@northwell.edu
50
51

52 2,761 words

53 5 tables/figure
54
55
56
57
58
59
60

Abstract (300/300 words)

Objective: To describe the pattern of hydroxychloroquine use and examine the association between hydroxychloroquine use and clinical outcomes arising from changes in the U.S. Food and Drug Administration (FDA)'s recommendation during the COVID-19 pandemic.

Design: A retrospective cross-sectional analysis.

Setting and Participants: We included hospitalized adult patients at Northwell Health hospitals with confirmed COVID-19 infections between March 1, 2020 and May 11, 2020. We categorized changes in the FDA recommendation as pre-FDA approval (March 1-March 27, 2020), FDA approval (March 28-April 23, 2020), and FDA warning (April 24-May 11, 2020). The hydroxychloroquine treated group received at least one dose within 48 hours of hospital admission.

Primary outcome: A composite of intubation and inpatient death.

Results: The percentages of patients who were treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%) FDA approval, and 176/1066 (16.5%) FDA warning period (p-value<0.001). Using propensity score-matching, there was a higher rate of the composite outcome among patients treated with hydroxychloroquine (49/192, 25.5%) compared to no hydroxychloroquine (66/384, 17.2%) in the pre-FDA approval period (p-value=0.03) but not in the FDA-approval period (25.5% vs 22.6%, p=0.08) or the FDA warning (21.0% vs 15.1%, p=0.11) periods. Coincidentally, there was an increase in number of COVID-19 patients and disease severity during the FDA approval period (24.1% during FDA approval versus 21.4% during pre-FDA approval period). Hydroxychloroquine use was associated with increased odds of the composite outcome during the pre-FDA approval period (OR=1.65 [1.09-2.51]) but not

1
2
3 during the FDA approval (OR=1.17 [0.99-1.39]) and FDA warning (OR=1.50 [0.94-2.39])
4 periods.
5
6

7 **Conclusions:** Hydroxychloroquine use was associated with adverse clinical outcomes only
8 during the pre-FDA approval period but not during the FDA-approval and warning periods, even
9 after adjusting for concurrent changes in the percentage of COVID-19 patients treated with
10 hydroxychloroquine and the number (and disease severity) of hospitalized patients with COVID-
11 19 infections.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations

- This study provides insights into how changes in FDA recommendations impact physicians' behaviors during a pandemic.
- The study utilizes data from a large integrated health system, which include a diverse population throughout New York City, Long Island, and Westchester County.
- This study uses propensity score-matching within each FDA recommendation, to ensure that patients admitted in the FDA approval period are not matched to patients in the pre-FDA approval or FDA warning period.
- Due to the observational study design, this study does not establish causal relationship between hydroxychloroquine treatment and outcomes.

Introduction

Coronavirus Disease 2019 (COVID-19), which causes severe acute respiratory syndrome, has spread globally. One consequence has been the unprecedented number of intensive care unit (ICU) admissions requiring mechanical ventilation in many countries. The mortality of patients on mechanical ventilation has been reported to be 60-80% with an overall hospital mortality of 20-25% during the beginning of the pandemic.^{1,2} More recent studies have shown lower inpatient mortality, but COVID-19 still causes significant morbidity and mortality.^{3,4} As of November 11, 2020, over 53 million people have been infected with COVID-19 and 1.3 million deaths have been reported globally.⁵ Although multiple vaccines are in preparation or have begun clinical testing, data on safety and efficacy required to immunize the general public is currently unavailable and may be months to years away. Therefore, the need to identify medications that are associated with slowed COVID-19 progression or decreased mortality remains urgent.

During the early months of the COVID-19 pandemic, hydroxychloroquine, a medication commonly used to prevent malaria infection and treat autoimmune diseases, gained global attention for its effectiveness in treating COVID-19 *in vitro*.⁶⁻¹¹ Hydroxychloroquine is found to reduce the entry of coronavirus into a cell through interference with the terminal glycosylation of angiotensin-converting enzyme 2 receptor, which inhibits viral replication.^{6,8} Additionally, hydroxychloroquine has immunomodulatory activity, and may inhibit cytokine production and prevent the occurrence of cytokine storm.¹² Early studies examining the treatment of COVID-19 with hydroxychloroquine showed mixed results, with some studies showing no average benefit in outcomes, including intubation or inpatient mortality, but other studies showing worse outcomes.¹³⁻²² A recent randomized clinical trial study examining the effects of

1
2
3 hydroxychloroquine has found no difference in clinical outcomes between patients treated with
4
5 and without hydroxychloroquine.²³
6

7
8 However, no study has accounted for how changes in recommendations for
9
10 hydroxychloroquine by the United States Food and Drug Administration (FDA) affected
11
12 outcomes of patients treated for COVID-19. On March 28, 2020, the FDA issued an Emergency
13
14 Use Authorization for hydroxychloroquine in the treatment of COVID-19 infection. During this
15
16 time, there was also an increased number of hospitalized patients with COVID-19, which may
17
18 have resulted in changes in hospital capacity and disease severity.⁵ Subsequently, on April 24,
19
20 2020, the FDA cautioned against using hydroxychloroquine for COVID-19 infection.²⁴ These
21
22 changes in the recommendation of hydroxychloroquine as a treatment for COVID-19 infection
23
24 may have impacted whether patients were treated with hydroxychloroquine for COVID-19.
25
26 These two events occurring concurrently could affect the association between
27
28 hydroxychloroquine and COVID-19 outcomes. Therefore, using data from one of the largest
29
30 healthcare systems in the United States, we described the pattern of hydroxychloroquine use over
31
32 time according to the FDA's position and examined the association between hydroxychloroquine
33
34 use and patients' clinical outcomes based on changes in FDA recommendation.
35
36
37
38
39
40
41

42 **Methods**

43 *Setting*

44
45
46 This is a cross-sectional analysis of data from Northwell Health, the largest academic
47
48 healthcare system in New York. Northwell Health serves approximately 11 million patients
49
50 throughout Long Island, New York City, and Westchester County and has 23 affiliated
51
52 healthcare facilities, including 12 acute care hospitals. The Institutional Review Board for the
53
54
55
56
57
58
59
60

1
2
3 Feinstein Institutes for Medical Research at Northwell Health approved this case series as
4
5 minimal-risk research using data collected for routine clinical practice and waived the
6
7 requirement for informed consent.
8
9

10 11 12 *Data Source* 13

14
15 Data for this study was obtained from the enterprise's inpatient electronic health record
16
17 (EHR; Sunrise Clinical Manager, Allscripts, Chicago, IL), which covers 12 of Northwell
18
19 Health's hospitals.
20
21

22 23 24 *Study Population* 25

26
27 The study population included all adult patients (n=13,258), aged 18 years and older,
28
29 hospitalized at one of Northwell Health's 12 acute care hospitals between March 1, 2020 and
30
31 May 11, 2020 with a diagnosis of COVID-19 confirmed by a positive result on polymerase chain
32
33 reaction testing of a nasopharyngeal sample. For patients with multiple COVID-19 tests, they
34
35 were considered to have a confirmed COVID-19 infection if any of the repeated tests within the
36
37 same hospitalization returned positive. We excluded patients who died or were intubated within
38
39 one day of hospitalization because their clinical outcomes were likely predetermined by pre-
40
41 hospitalization factors. We also excluded patients who were discharged within one day of
42
43 admission. Patients who were admitted to the obstetrics service were excluded as all obstetrics
44
45 patients were screened for COVID-19 on their admission. For patients with multiple
46
47 hospitalizations for COVID-19, we used their first hospitalization with a confirmed diagnosis of
48
49 COVID-19. We excluded 3,249 patients who did not meet the inclusion and exclusion criteria.
50
51
52
53
54
55
56
57
58
59
60

Exposure

Patients were identified as treated with hydroxychloroquine if they received at least one dose within 48 hours of admission. The control group for this analysis consisted of patients who were not treated with hydroxychloroquine within 48 hours of admission. Patients who did not initially receive hydroxychloroquine within 48 hours but received the medication later in their hospitalization were kept in the control group. We excluded COVID-19 patients who were treated with azithromycin or a combination of hydroxychloroquine and azithromycin. We also excluded patients who were intubated prior to getting their first dose of hydroxychloroquine within 48 hours of admission.

Outcomes

The primary outcome of interest was a composite outcome of time to intubation or time to inpatient death. Time until composite event was censored at time of discharge for patients who were discharged alive with no intubation during their hospitalization. The rationale for the combined primary outcome was twofold: 1) many patients who deteriorated clinically died without being intubated, often due to transition to palliative care; and 2) hospitalization stays for intubated COVID-19 patients have been very long, and many intubated COVID-19 patients at the time of the analyses may not ultimately survive. For a sensitivity analysis, we used death as the outcome. We tracked all patients who were not discharged or died until June 1, 2020.

Covariates

We collected data on patients' demographic characteristics and comorbidities. Demographic characteristics included age, sex, race/ethnicity, and health insurance (commercial,

1
2
3 Medicaid, Medicare, other, and no insurance). We used patient-reported race and ethnicity
4 information and categorized patients into one of five racial/ethnic groups: White, Black, Asian,
5
6 information and categorized patients into one of five racial/ethnic groups: White, Black, Asian,
7
8 Other/Multiracial, and Unknown/Declined. We also identified a subgroup of patients who
9
10 received immunomodulatory medications, including steroids (prednisone or
11
12 methylprednisolone), sarilumab, tocilizumab, anakinra, or colchicine, and included this
13
14 information as a covariate. We identified the presence of the following comorbidities by
15
16 *International Statistical Classification of Disease and Related Health Problems, Tenth Revision*
17
18 *(ICD-10)* coding: cancer, coronary artery disease, hypertension, asthma, chronic obstructive
19
20 pulmonary disease, diabetes, chronic liver disease, chronic kidney disease, and end stage renal
21
22 disease. We calculated the Charlson Comorbidity Index, which is an index that predicts the 10-
23
24 year survival of patients with multiple comorbidities, as a measure of total comorbidity burden.²⁵
25
26 The only covariate with missing data was BMI, and we categorized the BMI group as not obese
27
28 (BMI less than 30kg/m²), obese (BMI greater than or equal to 30kg/m²), and missing BMI.
29
30

31
32
33 We categorized changes in FDA recommendation for hydroxychloroquine, into three
34
35 time periods: 1) pre-FDA approval (March 1-March 27, 2020); 2) FDA approval (March 28-
36
37 April 23, 2020); and 3) FDA warning (April 24-May 11, 2020).
38
39

40 41 42 *Statistical analysis*

43
44 All analyses were performed using version 3.5.2 of the R Programming Language (R
45
46 Project for Statistical Computing, R Foundation, Vienna, Austria). We first performed chi-square
47
48 and 2-sample t-tests to compare patient characteristics treated with hydroxychloroquine to no
49
50 hydroxychloroquine (control).
51
52
53
54
55
56
57
58
59
60

1
2
3 We used propensity-score matching methods, 1:2 for the pre-FDA approval and the FDA
4 warning periods and 1:1 for the FDA approval period, using the smaller group as a reference,
5 within each period and applied the nearest-neighbor method to create a matched control sample.
6
7 The propensity-score matching was performed within each period so that patients admitted
8 within the FDA approval period were not matched to patients in the pre-FDA approval or FDA
9 warning periods, so as not to confound the effect of different FDA recommendations.
10
11
12
13
14
15
16

17 We then took the following approach to conduct the analysis. We first performed logistic
18 regressions to compare the propensity score-matched hydroxychloroquine group to the control
19 group. For a time-to-event analysis, we used the Kaplan-Meier survival estimate and log-rank
20 test. We examined the Kaplan-Meier survival curves for the treatment group compared to the
21 control group, separated by the different FDA recommendation periods. If a patient was
22 discharged alive without intubation, data was censored at the time of hospital discharge. Then,
23 we used Cox proportional-hazard regression models to estimate the association between the
24 propensity-matched treatment group to the control group with respect to end point free survival
25 time. We used the Schoenfeld residuals to test the proportional hazard assumption in the Cox
26 model.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Results**

43 *Characteristics of the cohort*

44
45 From a cohort of 10,009 patients, 3,270 (32.7%) were treated with hydroxychloroquine,
46 2,640 (26.4%) with neither hydroxychloroquine nor azithromycin, 1,289 (12.9%) with
47 azithromycin only, and 2,810 (28.1%) with the combination hydroxychloroquine and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 azithromycin. There were differences in the number of patients treated with or without
4 hydroxychloroquine and/or azithromycin by admission period (Figure 1).
5
6

7
8 We found significant differences in the use of hydroxychloroquine and patient
9 characteristics based on changes to FDA recommendation. Number and percentages of patients
10 treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%)
11 during FDA approval, and 176/1066 (16.5%) during the FDA warning period (p-value<0.001).
12 There was a significant increase in number of patients during the FDA approval period (March
13 28-April 23). During the pre-FDA approval period, there were 2,202 patients admitted with
14 COVID-19 infection, but in the following periods, the number of patients admitted with COVID-
15 19 infections was 6,741 (FDA approval period) and 1,066 (FDA warning period). Throughout
16 the study, and independent of FDA periods, there were differences in sociodemographic and
17 clinical characteristics between the treatment group compared to the control group (Table 1).
18 Higher percentage of patients who were younger (36.8% vs 32.5% were less than 60 years old),
19 male (59.9% vs 53.4%), and had commercial insurance (31.0% vs 24.2%) were treated with
20 hydroxychloroquine (p-values<0.001). Presence of comorbidity was associated with
21 hydroxychloroquine use (all p-values<0.05), except for asthma and diabetes, and chronic kidney
22 disease.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Hydroxychloroquine groups (13.4%) had higher rates of intubation compared to the
43 control group (7.0%) (p-value<0.001). Inpatient mortality was 20.2% for hydroxychloroquine
44 versus 18.3% for no hydroxychloroquine treatment (p-value=0.01). A significantly higher
45 percentage of patients treated with hydroxychloroquine (23.4%) reached the composite outcome
46 compared to the control group (20.4%) (p-value=0.007). A higher percentage of patients on
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 hydroxychloroquine (52.8%) were treated concurrently with immunomodulatory medications
4 compared to the control group (24.7%) (p-value<0.001).
5
6

7
8 After propensity-score matching within each time period, sociodemographic
9 characteristics and comorbidity were similar between hydroxychloroquine and no
10 hydroxychloroquine group (Table 2). There were 576 patients in the pre-FDA approval period,
11 2812 patients in the FDA approval period, and 528 FDA warning period. There was a higher
12 composite outcome among patients treated with hydroxychloroquine (25.5%) compared to no
13 hydroxychloroquine (17.2%) during the pre-FDA approval period (p-value=0.03) but no
14 difference in the number of composite outcomes between hydroxychloroquine and no
15 hydroxychloroquine groups in the FDA-approval period (25.5%, vs 22.6% p=0.08) or the FDA
16 warning period (21.0 vs 15.1% %, p=0.11) (Table 3). In the univariate analysis,
17 hydroxychloroquine use was associated with increased odds of the composite outcome during the
18 pre-FDA approval period (OR=1.65 [1.09-2.51]) but there was no association during the FDA
19 approval (OR=1.17 [0.99-1.39]) as well as the FDA warning period (OR=1.50 [0.94-2.39]).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 *Time-to event analysis*

39
40 Figure 2 shows the Kaplan-Meier curves of freedom from the composite end point of
41 intubation and inpatient mortality during the pre-FDA approval period, the FDA approval period,
42 or the FDA warning period. The cox proportional-hazard regression models showed
43 hydroxychloroquine use was associated with the composite outcome of intubation and inpatient
44 mortality during the pre-FDA approval (hazard ratio=1.70 [1.17-2.48]) and the FDA warning
45 (hazard ratio=1.53 [1.00-2.34]) period but not during the FDA approval period (hazard
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ratio=1.03 [0.88-1.20]) (Table 3). The proportional hazards assumption was met in the cox
4
5 regression model.
6
7
8
9
10

11 **Discussion**

12
13
14 In our study, while there were changes in percentage of COVID-19 patients treated with
15 hydroxychloroquine with FDA recommendations, there was also a fluctuation of the number of
16 hospitalized patients with COVID-19 infections during the FDA approval period.
17
18 Hydroxychloroquine treatment was associated with increased composite outcome of intubation
19 or death during pre-FDA approval period but not during FDA approval or FDA warning period.
20
21 The overall association of hydroxychloroquine treatment among COVID-19 patients in our
22 cohort was similar to previous studies showing no association between the treatment and primary
23 end point of intubation or death.^{13,14}
24
25
26
27
28
29
30
31
32

33 Although not captured in our study, hospitals during the FDA approval period had to
34 manage sudden increases in critically ill patients. As hospitals were reaching their maximum
35 capacity, coordinated efforts were made to ensure that there were adequate ventilators for
36 patients with pulmonary complications, goals of care discussions for patients with poor
37 prognosis, and an increase in ambulatory management to ensure medical care for all patients.²⁶⁻²⁸
38
39 Therefore, patients who were admitted during this period may have had more severe disease,
40 including hypoxia, requiring ventilators. This hypothesis is also consistent with the higher
41 proportions of patients experiencing the composite outcome during this period. There was also
42 an increased use of immunomodulators, which were more often used for patients with more
43 complications, including acute respiratory distress syndrome, acute kidney injury, thrombosis,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 etc.^{1,29,30} Therefore, regardless of whether they were being treated with hydroxychloroquine or
4
5 not, patients admitted during the FDA approval period had overall worse outcomes compared to
6
7 patients admitted during other periods. Because of such differences in patient disease severity
8
9 and hospital settings, we used propensity-score matching of patients within each period so that
10
11 the patients treated in the pre-FDA approval or FDA warning periods were not matched with
12
13 patients treated in the FDA approval period.
14
15

16
17 The lack of efficacy of hydroxychloroquine could be attributed to the severity of disease
18
19 among patients receiving medication. The hypothesized mechanism of action of
20
21 hydroxychloroquine is that it prevents the virus from entering cells and blocks viral replication.⁶⁻
22
23 ⁸ These patients were hospitalized because of a severe course of disease, and therefore it is likely
24
25 that viral replication was already high when hydroxychloroquine was administered. This may be
26
27 particularly true for patients who were hospitalized during the FDA approved period because
28
29 hospitals had a high number of COVID-19 patients requiring inpatient care. Also,
30
31 hydroxychloroquine may have been administered to more severely ill patients and subsequently
32
33 was associated with higher risk of intubation and/or inpatient mortality. We addressed this by
34
35 propensity-score matching patients treated with hydroxychloroquine to no hydroxychloroquine.
36
37 Of note, higher doses of hydroxychloroquine have been associated with adverse intermediate
38
39 outcomes, including QTc prolongation, in another study.³¹
40
41
42
43

44
45 This study has several limitations. Due to the observational study design, this study does
46
47 not establish causal relationships between medication treatment and outcomes. Also, this study is
48
49 limited to the inpatient setting, therefore the study findings are not generalizable to outpatient or
50
51 community settings. Though we did attempt to adjust for covariates, it is possible that the
52
53 severity of illness and precise timing of treatment also may have influenced the association of
54
55
56
57
58
59
60

1
2
3 these medications with the outcome. There might be a subset of patients who were taking
4 hydroxychloroquine prescribed by their ambulatory providers prior to their hospitalization. It is
5 possible that some patients in the no hydroxychloroquine group were taking the medications or
6 already had completed their 5-day course prior to hospitalization. There was a subset of patients
7 in the control group who were treated with hydroxychloroquine or azithromycin after 48 hours
8 because of their disease progression. The changes in the FDA recommendations probably also
9 caused some patients admitted during the pre-FDA approval period to be treated with
10 hydroxychloroquine during their prolonged hospitalizations. This could result in bias toward the
11 null, that is, erroneously concluding no difference between hydroxychloroquine and control
12 (Type II error). The strength of this study, however, is the inclusion of a large, diverse
13 population, including racial and ethnic minorities, extending the generalizability of our study.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Regardless of FDA's recommendation for the drug, we did not observe any beneficial
29 association of hydroxychloroquine use throughout the study period. In addition to changes in the
30 FDA recommendation, this study addresses changes in case mix due to changes in number of
31 COVID-19 patients being hospitalized. This study further confirms that hydroxychloroquine
32 does not alter the clinical course among patients with COVID-19 infections in the inpatient
33 setting where patients have more severe diseases. Additionally, recent evidence suggests that
34 hydroxychloroquine treatment does not alter clinical outcomes among patients with milder
35 symptoms and is not effective as pharmacologic prophylaxis.^{32,33} On June 15, 2020, the FDA
36 revoked the Emergency Use Authorization for hydroxychloroquine in the treatment of COVID-
37 19 infection and this will further decrease the number of COVID-19 patients being treated with
38 hydroxychloroquine.³⁴ These study results should not be used as guidance on whether or not to
39 treat COVID-19 patients with or without hydroxychloroquine due to its observational design.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data Availability Statement

The data that support the findings of this study are available on request from COVID19@northwell.edu. The data are not publicly available due to restrictions as it could compromise the privacy of research participants.

Conflict of Interest Disclosures

The authors report no real or apparent conflicts of interest.

Funding/Support

This work was supported by grants R24AG064191 from the National Institute on Aging of the National Institutes of Health and R01LM012836 from the National Library of Medicine of the National Institutes of Health.

Role of the Funder/Sponsor

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this paper are those of the authors and do not represent the views of the National Institutes of Health, the United States Department of Health and Human Services, or any other government entity.

Patient and Public Involvement

1
2
3 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
4 plans of our research.
5
6
7
8
9

10 **Figures**

11
12 Figure 1. Number of COVID-19 patients treated with different medications
13

14 Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or
15 inpatient mortality by different time period
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020.
3. Angeli F, Bachetti T, Maugeri Study G. Temporal changes in co-morbidities and mortality in patients hospitalized for COVID-19 in Italy. *Eur J Intern Med.* 2020.
4. Horwitz LI, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. *J Hosp Med.* 2020.
5. The Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Published 2020. Accessed June 10, 2020.
6. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020.
7. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-271.
8. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J.* 2005;2:69.
9. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* 2020;6:16.
10. Andreani J, Le Bideau M, Dufloy I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020;145:104228.
11. Grassin-Delyle S, Salvator H, Brollo M, et al. Chloroquine inhibits the release of inflammatory cytokines by human lung explants. *Clin Infect Dis.* 2020.
12. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol.* 2020;16(3):155-166.
13. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020.
14. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA.* 2020.
15. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ.* 2020;369:m1849.
16. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect.* 2020;50(4):384.
17. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv.* 2020.
18. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus

- disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2020.
19. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020;105949.
 20. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends.* 2020;14(1):72-73.
 21. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv.* 2020.
 22. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis.* 2020;97:396-403.
 23. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA.* 2020.
 24. Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. U.S. Food & Drug Administration <https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use>. Accessed May 15, 2020.
 25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
 26. Curtis JR, Kross EK, Stapleton RD. The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019 (COVID-19). *JAMA.* 2020.
 27. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *BMJ.* 2020;368:m1182.
 28. White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic. *JAMA.* 2020.
 29. Hirsch JS, Ng JH, Ross DW, et al. Acute Kidney Injury in Patients Hospitalized with Covid-19. *Kidney Int.* 2020.
 30. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood.* 2020;135(23):2033-2040.
 31. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open.* 2020;3(4):e208857.
 32. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Intern Med.* 2020.
 33. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med.* 2020;383(6):517-525.

- 1
2
3 34. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for
4 Chloroquine and Hydroxychloroquine. U.S. Foods and Drug Administration.
5 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
6 [fda-revokes-emergency-use-authorization-chloroquine-and](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and). Published June 15, 2020.
7 Accessed June 20, 2020.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Patient characteristics before propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	All (n=10,009)	HCQ (n=3,270)	No HCQ (n=2,640)	P-value*
Sociodemographic characteristics				
Age at admission, mean (SD)	64.99 (16.35)	64.29 (15.58)	66.87 (17.73)	<0.001
Age group				<0.001
18-49	1747 (17.5)	558 (17.1)	434 (16.4)	
50-59	1863 (18.6)	645 (19.7)	425 (16.1)	
60-69	2277 (22.7)	816 (25.0)	530 (20.1)	
70-79	2046 (20.4)	671 (20.5)	518 (19.6)	
80+	2076 (20.7)	580 (17.7)	733 (27.8)	
Male	5847 (58.4)	1959 (59.9)	1411 (53.4)	<0.001
Race				<0.001
White	3923 (39.2)	1151 (35.2)	1182 (44.8)	
Black	2104 (21.0)	632 (19.3)	581 (22.0)	
Asian	849 (8.5)	327 (10.0)	236 (8.9)	
Other/Multiracial	2648 (26.5)	958 (29.3)	540 (20.5)	
Unknown	485 (4.8)	202 (6.2)	101 (3.8)	
Health insurance				<0.001
Commercial	2947 (29.4)	1013 (31.0)	638 (24.2)	
Medicaid	2041 (20.4)	712 (21.8)	488 (18.5)	
Medicare	4754 (47.5)	1431 (43.8)	1453 (55.0)	
Other	133 (1.3)	46 (1.4)	45 (1.7)	
No insurance	134 (1.3)	68 (2.1)	16 (0.6)	
Comorbidity				
Cancer	832 (8.3)	238 (7.3)	278 (10.5)	<0.001
Coronary artery disease	1339 (13.4)	399 (12.2)	429 (16.2)	<0.001
Hypertension	6073 (60.7)	1973 (60.3)	1673 (63.4)	0.02
Peripheral artery/vascular disease	282 (2.8)	81 (2.5)	100 (3.8)	0.005
Asthma	842 (8.4)	271 (8.3)	198 (7.5)	0.29
Chronic obstructive pulmonary disease	639 (6.4)	168 (5.1)	174 (6.6)	0.02
Diabetes	3624 (36.2)	1233 (37.7)	945 (35.8)	0.14
Chronic liver disease	298 (3.0)	74 (2.3)	110 (4.2)	<0.001
Chronic kidney disease	507 (5.1)	155 (4.7)	152 (5.8)	0.09
End stage renal disease	461 (4.6)	144 (4.4)	168 (6.4)	0.001
Charlson Comorbidity Index, mean SD	4.89 (3.58)	4.56 (3.38)	5.74 (3.77)	<0.001
Obesity				<0.001
Obese	2810 (28.1)	1001 (30.6)	570 (21.6)	
Not obese	4632 (46.3)	1483 (45.4)	1296 (49.1)	
Missing BMI	2567 (25.6)	786 (24.0)	774 (29.3)	
BMI, mean (SD)	29.23 (7.06)	29.66 (7.04)	28.13 (7.14)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Clinical outcomes**

Admission week				<0.001
Pre-FDA approval	2202 (22.0)	192 (5.9)	496 (18.8)	
FDA approval	6741 (67.3)	2902 (88.7)	1406 (53.3)	
FDA warning	1066 (10.7)	176 (5.4)	738 (28.0)	
Length of stay, mean (SD)	9.51 (9.60)	9.56 (9.14)	8.80 (9.27)	0.001
Immunomodulator use	4183 (41.8)	1727 (52.8)	651 (24.7)	<0.001
ICU stay	1985 (19.8)	583 (17.8)	426 (16.1)	0.09
Mechanical ventilation	1314 (13.1)	437 (13.4)	186 (7.0)	<0.001
Inpatient mortality	1983 (19.8)	660 (20.2)	482 (18.3)	0.01
Composite Outcome	2413 (24.1)	764 (23.4)	538 (20.4)	0.007

* Comparing hydroxychloroquine group to no treatment group

Table 2. Patient characteristics after propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	Pre-FDA approval				FDA approval				FDA warning			
	HCQ (n=192)	No HCQ (n=384)	P- value*	SMD	HCQ (n=1406)	No HCQ (n=1406)	P- value*	SMD	HCQ (n=176)	No HCQ (n=352)	P- value*	SMD
Sociodemographic characteristics												
Age at admission, mean (SD)	61.1 (15.8)	62.8 (17.2)	0.26	0.101	67.8 (15.8)	67.3 (17.6)	0.42	0.03	66.2 (16.2)	66.3 (17.6)	0.94	0.007
Male	109 (56.8)	218 (56.8)	1.00	0.01	740 (52.6)	765 (54.4)	0.36	0.036	92 (52.3)	194 (55.1)	0.60	0.057
Race			0.68	0.134			1.00	0.013			0.99	0.05
White	91 (47.4)	180 (46.9)			610 (43.4)	612 (43.5)			65 (36.9)	136 (38.6)		
Black	35 (18.2)	86 (22.4)			306 (21.8)	302 (21.5)			37 (21.0)	69 (19.6)		
Asian	17 (8.9)	37 (9.6)			143 (10.2)	143 (10.2)			12 (6.8)	25 (7.1)		
Other/Multiracial	44 (22.9)	72 (18.8)			297 (21.1)	296 (21.1)			53 (30.1)	106 (30.1)		
Unknown	5 (2.6)	9 (2.3)			50 (3.6)	53 (3.8)			9 (5.1)	16 (4.5)		
Health insurance			0.02	0.257			0.90	0.039			1.00	0.036
Commercial	91 (47.4)	134 (34.9)			306 (21.8)	321 (22.8)			44 (25.0)	92 (26.1)		
Medicaid	30 (15.6)	72 (18.8)			246 (17.5)	249 (17.7)			31 (17.6)	62 (17.6)		
Medicare	71 (37.0)	178 (46.4)			819 (58.3)	805 (57.3)			92 (52.3)	182 (51.7)		
Other	0 (0.0)	0 (0.0)			27 (1.9)	22 (1.6)			6 (3.4)	11 (3.1)		
No insurance	0 (0.0)	0 (0.0)			8 (0.6)	9 (0.6)			3 (1.7)	5 (1.4)		
Comorbidity												
Cancer	10 (5.2)	25 (6.5)	0.67	0.055	134 (9.5)	151 (10.7)	0.32	0.04	16 (9.1)	30 (8.5)	0.96	0.02
Coronary artery disease	23 (12.0)	56 (14.6)	0.47	0.077	218 (15.5)	222 (15.8)	0.88	0.008	27 (15.3)	53 (15.1)	1.00	0.008
Hypertension	109 (56.8)	237 (61.7)	0.29	0.101	915 (65.1)	884 (62.9)	0.24	0.046	107 (60.8)	205 (58.2)	0.64	0.052
Peripheral artery/vascular disease	7 (3.6)	13 (3.4)	1.00	0.014	48 (3.4)	42 (3.0)	0.59	0.024	6 (3.4)	6 (1.7)	0.35	0.108
Asthma	24 (12.5)	35 (9.1)	0.26	0.109	88 (6.3)	100 (7.1)	0.41	0.034	17 (9.7)	32 (9.1)	0.96	0.019
Chronic obstructive pulmonary disease	9 (4.7)	23 (6.0)	0.65	0.058	83 (5.9)	87 (6.2)	0.81	0.012	14 (8.0)	29 (8.2)	1.00	0.01
Diabetes	70 (36.5)	138 (35.9)	0.98	0.011	515 (36.6)	508 (36.1)	0.81	0.01	68 (38.6)	131 (37.2)	0.82	0.029
Chronic liver disease	7 (3.6)	15 (3.9)	1.00	0.014	47 (3.3)	56 (4.0)	0.42	0.034	7 (4.0)	19 (5.4)	0.62	0.067
Chronic kidney disease	11 (5.7)	25 (6.5)	0.86	0.033	84 (6.0)	80 (5.7)	0.81	0.012	8 (4.5)	17 (4.8)	1.00	0.013

1													
2													
3	End stage renal												<0.0
4	disease	12 (6.2)	27 (7.0)	0.86	0.031	99 (7.0)	101 (7.2)	0.94	0.006	4 (2.3)	8 (2.3)	1.00	01
5	Charlson												
6	Comorbidity Index,									5.03			
7	mean SD	4.23 (3.19)	4.73 (3.32)	0.09	0.152	5.72 (3.75)	5.69 (3.73)	0.84	0.008	(3.23)	5.01 (3.42)	0.96	0.005
8	Obesity			0.08	0.198			0.84	0.022			0.96	0.027
9	Obese	76 (39.6)	116 (30.2)			289 (20.6)	292 (20.8)			50 (28.4)	98 (27.8)		
10	Not obese	69 (35.9)	160 (41.7)			678 (48.2)	663 (47.2)			84 (47.7)	166 (47.2)		
11	Missing BMI	47 (24.5)	108 (28.1)			439 (31.2)	451 (32.1)			42 (23.9)	88 (25.0)		
12	Clinical outcomes												
13	Length of stay, mean	10.88	10.48					<0.00		8.67			
14	(SD)	(11.20)	(11.79)	0.70	0.035	9.29 (8.66)	7.75 (7.82)	1	0.187	(7.55)	8.28 (7.40)	0.57	0.053
15	Mechanical							<0.00					
16	ventilation	33 (17.2)	29 (7.6)	0.001	0.296	168 (11.9)	85 (6.0)	1	0.207	26 (14.8)	25 (7.1)	0.008	0.248
17	Inpatient mortality	31 (16.1)	55 (14.3)	0.32	0.272	318 (22.6)	294 (20.9)	0.32	0.086	32 (18.2)	46 (13.1)	1.00	0.079
18	Composite Outcome	49 (25.5)	66 (17.2)	0.03	0.204	359 (25.5)	318 (22.6)	0.08	0.068	37 (21.0)	53 (15.1)	0.11	0.156

* Comparing hydroxychloroquine group to no treatment group

SMD=Standardized mean difference

Table 3. Association between hydroxychloroquine use and the composite end point in the crude analysis and propensity-score matched analysis

Analysis	Results	P-value*
Composite outcome among patients at risk, n (%)		
Before propensity score matching		
All periods		
Overall	2080/10009 (23.9)	-
Hydroxychloroquine	764/3270 (23.4)	0.007
No HCQ	538/2640 (20.4)	
After propensity score matching		
Pre-FDA approval		
Hydroxychloroquine	49/192 (25.5)	0.03
No HCQ	66/384 (17.2)	
FDA approval		
Hydroxychloroquine	359/1406 (25.5)	0.08
No HCQ	318/1406 (22.6)	
FDA warning		
Hydroxychloroquine	37/176 (21.0)	0.11
No HCQ	53/352 (15.1)	
Univariate analysis - odds ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.65 [1.09-2.51]	0.02
FDA approval (reference: no HCQ)	1.17 [0.99-1.39]	0.07
FDA warning (reference: no HCQ)	1.50 [0.94-2.39]	0.09
Propensity-score matched analyses-hazard ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.70 [1.17-2.48]	0.005
FDA approval (reference: no HCQ)	1.03 [0.88-1.20]	0.72
FDA warning (reference: no HCQ)	1.53 [1.00-2.34]	0.05

* Comparing hydroxychloroquine group to no treatment group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47






Figure 1. Trends in COVID-19 patients treated with different medications



a. Pre-FDA approval

Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or inpatient mortality by different time period




		Number at risk				
		0	7	14	21	28
Txt Group	No Txt	1406	498	148	60	27
	HCQ	1406	589	158	54	24

Time

b. FDA approval

Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or inpatient mortality by different time period



c. FDA warning

Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or inpatient mortality by different time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 and 3
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 5 and 6
Objectives	3	State specific objectives, including any prespecified hypotheses Page 6 lines 13-16
Methods		
Study design	4	Present key elements of study design early in the paper Page 6 line 20
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 6 lines 19-Page 7 line 3, Page 7 lines 11-14, Page 8 lines 19
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants Page 7 lines 10-22
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 8 lines 4-Page 9 line 16
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 7 lines 5- 8
Bias	9	Describe any efforts to address potential sources of bias Page 10 lines 1-6
Study size	10	Explain how the study size was arrived at Page 7 lines 10-22
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 8 line 21- Page 9 line 13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 9 line 18-Page 10 line 16 (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed Page 9 lines 12-13 (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses Page 8 lines 18-19
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 7 lines 11-15, line 22 (b) Give reasons for non-participation at each stage

		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 10 line 20-page 12 line 14
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures Page 12 lines 6-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 12 lines 6-Page 13 line 2
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives Page 13 lines 5-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14 line 18-Page 15 line 9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 14 lines 6-17
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 15 lines 9-10
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 16 lines 9-12

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Examination of patient characteristics and hydroxychloroquine use based on U.S. Food and Drug Administration's recommendation: a cross-sectional analysis in New York

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042965.R2
Article Type:	Original research
Date Submitted by the Author:	23-Dec-2020
Complete List of Authors:	Kim, Eun Ji; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Coppa, Kevin; Northwell Health Hirsch, Jamie; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research, Abrahams, Sara; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Johnson, Jennifer; Northwell Health Feinstein Institutes for Medical Research, Lesser, Martin; Northwell Health Feinstein Institutes for Medical Research, Biostatistics; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Davidson, Karina W.; Feinstein Institute for Medical Research, Research; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Conigliaro, Joseph; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Northwell Health Feinstein Institutes for Medical Research,
Primary Subject Heading:	Global health
Secondary Subject Heading:	Epidemiology, Health policy, Health services research, Infectious diseases, Medical management
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Examination of patient characteristics and hydroxychloroquine use based on U.S.**
4 **Food and Drug Administration's recommendation: a cross-sectional analysis in New York**
5

6 Eun Ji Kim, MD, MS, MS^{1,2}
7 Kevin Coppa, BS³
8 Jamie S. Hirsch, MD, MA, MSB^{1,2,3}
9 Sara Abrahams, BS²
10 Jennifer C. Johnson MS, MA¹
11 Martin Lesser PhD^{1,2}
12 Karina W. Davidson, PhD, MASc^{1,2}
13 Joseph Conigliaro, MD, MPH^{1,2}
14
15

16
17 The Northwell COVID-19 Research Consortium: Stuart L. Cohen, MD^{1,2}; Charlotte
18 Kvasnovsky, MD, PhD, MPH²; Stephen C. Machnicki, MD FCCP²; Alex Makhnevich MD^{1,2};
19 Prashant Malhotra, MD^{1,2}; Lyndonna Marrast, MD, MPH^{1,2}; Ramanak Mitra, MD²; Ernesto P.
20 Molmenti, MD²; Sonali Narain, MBBS, MPH^{1,2}; M. Wasif Saif MD, MBBS^{1,2}; Sanjaya
21 Satapathy, MD²; Shalin Shah, MD²
22
23

24 ¹ Institute of Health Innovations and Outcome Research, Feinstein Institutes for Medical
25 Research, Northwell Health, Manhasset, New York

26 ² Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health,
27 Hempstead, New York

28 ³ Department of Information Services, Northwell Health, New Hyde Park, New York
29
30
31

32 Contributorship Statement

33 Concept and design: EK, KC, JH, KD, ML, JC, SC, SM, AM, PM, LM, RM, EM, SN, WS, SS

34 Acquisition: KC, JH

35 Drafting of the manuscript: EK, KC, JC, SA, JJ

36 Critical revision of the manuscript for important intellectual content: all authors

37 Statistical analysis: KC, ML, CK

38 Obtained funding: KD

39 Administrative, technical or material support: KD, JC

40 Supervision: EK, ML, KD, JH, JC
41
42
43
44
45

46 Corresponding author: Joseph Conigliaro, MD, MPH

47 2001 Marcus Avenue S160

48 Lake Success, NY 11042

49 jconigliaro@northwell.edu
50

51 2,761 words

52 5 tables/figure
53
54
55
56
57
58
59
60

Abstract (300/300 words)

Objective: To describe the pattern of hydroxychloroquine use and examine the association between hydroxychloroquine use and clinical outcomes arising from changes in the U.S. Food and Drug Administration (FDA)'s recommendation during the COVID-19 pandemic.

Design: A retrospective cross-sectional analysis.

Setting and Participants: We included hospitalized adult patients at Northwell Health hospitals with confirmed COVID-19 infections between March 1, 2020 and May 11, 2020. We categorized changes in the FDA recommendation as pre-FDA approval (March 1-March 27, 2020), FDA approval (March 28-April 23, 2020), and FDA warning (April 24-May 11, 2020). The hydroxychloroquine treated group received at least one dose within 48 hours of hospital admission.

Primary outcome: A composite of intubation and inpatient death.

Results: The percentages of patients who were treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%) FDA approval, and 176/1066 (16.5%) FDA warning period (p-value<0.001). Using propensity score-matching, there was a higher rate of the composite outcome among patients treated with hydroxychloroquine (49/192, 25.5%) compared to no hydroxychloroquine (66/384, 17.2%) in the pre-FDA approval period (p-value=0.03) but not in the FDA-approval period (25.5% vs 22.6%, p=0.08) or the FDA warning (21.0% vs 15.1%, p=0.11) periods. Coincidentally, there was an increase in number of COVID-19 patients and disease severity during the FDA approval period (24.1% during FDA approval versus 21.4% during pre-FDA approval period). Hydroxychloroquine use was associated with increased odds of the composite outcome during the pre-FDA approval period (OR=1.65 [1.09-2.51]) but not

1
2
3 during the FDA approval (OR=1.17 [0.99-1.39]) and FDA warning (OR=1.50 [0.94-2.39])
4 periods.
5
6

7 **Conclusions:** Hydroxychloroquine use was associated with adverse clinical outcomes only
8 during the pre-FDA approval period but not during the FDA-approval and warning periods, even
9 after adjusting for concurrent changes in the percentage of COVID-19 patients treated with
10 hydroxychloroquine and the number (and disease severity) of hospitalized patients with COVID-
11 19 infections.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations

- This study examines hydroxychloroquine use with changes in the FDA recommendations during a COVID-19 pandemic.
- The study utilizes data from a large integrated health system, which include a diverse population throughout New York City, Long Island, and Westchester County.
- This study uses propensity score-matching within each FDA recommendation, to ensure that patients admitted in the FDA approval period are not matched to patients in the pre-FDA approval or FDA warning period.
- Due to the observational study design, this study does not establish causal relationship between hydroxychloroquine treatment and COVID-19 clinical outcomes.

Introduction

Coronavirus Disease 2019 (COVID-19), which causes severe acute respiratory syndrome, has spread globally. One consequence has been the unprecedented number of intensive care unit (ICU) admissions requiring mechanical ventilation in many countries. The mortality of patients on mechanical ventilation has been reported to be 60-80% with an overall hospital mortality of 20-25% during the beginning of the pandemic.^{1,2} More recent studies have shown lower inpatient mortality, but COVID-19 still causes significant morbidity and mortality.^{3,4} As of November 11, 2020, over 53 million people have been infected with COVID-19 and 1.3 million deaths have been reported globally.⁵ Although multiple vaccines are in preparation or have begun clinical testing, data on safety and efficacy required to immunize the general public is currently unavailable and may be months to years away. Therefore, the need to identify medications that are associated with slowed COVID-19 progression or decreased mortality remains urgent.

During the early months of the COVID-19 pandemic, hydroxychloroquine, a medication commonly used to prevent malaria infection and treat autoimmune diseases, gained global attention for its effectiveness in treating COVID-19 *in vitro*.⁶⁻¹¹ Hydroxychloroquine is found to reduce the entry of coronavirus into a cell through interference with the terminal glycosylation of angiotensin-converting enzyme 2 receptor, which inhibits viral replication.^{6,8} Additionally, hydroxychloroquine has immunomodulatory activity, and may inhibit cytokine production and prevent the occurrence of cytokine storm.¹² Early studies examining the treatment of COVID-19 with hydroxychloroquine showed mixed results, with some studies showing no average benefit in outcomes, including intubation or inpatient mortality, but other studies showing worse outcomes.¹³⁻²² A recent randomized clinical trial study examining the effects of

1
2
3 hydroxychloroquine has found no difference in clinical outcomes between patients treated with
4
5 and without hydroxychloroquine.²³
6

7
8 However, no study has accounted for how changes in recommendations for
9
10 hydroxychloroquine by the United States Food and Drug Administration (FDA) affected
11
12 outcomes of patients treated for COVID-19. On March 28, 2020, the FDA issued an Emergency
13
14 Use Authorization for hydroxychloroquine in the treatment of COVID-19 infection. During this
15
16 time, there was also an increased number of hospitalized patients with COVID-19, which may
17
18 have resulted in changes in hospital capacity and disease severity.⁵ Subsequently, on April 24,
19
20 2020, the FDA cautioned against using hydroxychloroquine for COVID-19 infection.²⁴ These
21
22 changes in the recommendation of hydroxychloroquine as a treatment for COVID-19 infection
23
24 may have impacted whether patients were treated with hydroxychloroquine for COVID-19.
25
26 These two events occurring concurrently could affect the association between
27
28 hydroxychloroquine and COVID-19 outcomes. Therefore, using data from one of the largest
29
30 healthcare systems in the United States, we described the pattern of hydroxychloroquine use over
31
32 time according to the FDA's position and examined the association between hydroxychloroquine
33
34 use and patients' clinical outcomes based on changes in FDA recommendation.
35
36
37
38
39
40
41

42 **Methods**

43 *Setting*

44
45 This is a cross-sectional analysis of data from Northwell Health, the largest academic
46
47 healthcare system in New York. Northwell Health serves approximately 11 million patients
48
49 throughout Long Island, New York City, and Westchester County and has 23 affiliated
50
51 healthcare facilities, including 12 acute care hospitals. The Institutional Review Board for the
52
53
54
55
56
57
58
59
60

1
2
3 Feinstein Institutes for Medical Research at Northwell Health approved this case series as
4
5 minimal-risk research using data collected for routine clinical practice and waived the
6
7 requirement for informed consent.
8
9

10 11 12 *Data Source* 13

14
15 Data for this study was obtained from the enterprise's inpatient electronic health record
16
17 (EHR; Sunrise Clinical Manager, Allscripts, Chicago, IL), which covers 12 of Northwell
18
19 Health's hospitals.
20
21

22 23 24 *Study Population* 25

26
27 The study population included all adult patients (n=13,258), aged 18 years and older,
28
29 hospitalized at one of Northwell Health's 12 acute care hospitals between March 1, 2020 and
30
31 May 11, 2020 with a diagnosis of COVID-19 confirmed by a positive result on polymerase chain
32
33 reaction testing of a nasopharyngeal sample. For patients with multiple COVID-19 tests, they
34
35 were considered to have a confirmed COVID-19 infection if any of the repeated tests within the
36
37 same hospitalization returned positive. We excluded patients who died or were intubated within
38
39 one day of hospitalization because their clinical outcomes were likely predetermined by pre-
40
41 hospitalization factors. We also excluded patients who were discharged within one day of
42
43 admission. Patients who were admitted to the obstetrics service were excluded as all obstetrics
44
45 patients were screened for COVID-19 on their admission. For patients with multiple
46
47 hospitalizations for COVID-19, we used their first hospitalization with a confirmed diagnosis of
48
49 COVID-19. We excluded 3,249 patients who did not meet the inclusion and exclusion criteria.
50
51
52
53
54
55
56
57
58
59
60

Exposure

Patients were identified as treated with hydroxychloroquine if they received at least one dose within 48 hours of admission. The control group for this analysis consisted of patients who were not treated with hydroxychloroquine within 48 hours of admission. Patients who did not initially receive hydroxychloroquine within 48 hours but received the medication later in their hospitalization were kept in the control group. We excluded COVID-19 patients who were treated with azithromycin or a combination of hydroxychloroquine and azithromycin. We also excluded patients who were intubated prior to getting their first dose of hydroxychloroquine within 48 hours of admission.

Outcomes

The primary outcome of interest was a composite outcome of time to intubation or time to inpatient death. Time until composite event was censored at time of discharge for patients who were discharged alive with no intubation during their hospitalization. The rationale for the combined primary outcome was twofold: 1) many patients who deteriorated clinically died without being intubated, often due to transition to palliative care; and 2) hospitalization stays for intubated COVID-19 patients have been very long, and many intubated COVID-19 patients at the time of the analyses may not ultimately survive. For a sensitivity analysis, we used death as the outcome. We tracked all patients who were not discharged or died until June 1, 2020.

Covariates

We collected data on patients' demographic characteristics and comorbidities. Demographic characteristics included age, sex, race/ethnicity, and health insurance (commercial,

1
2
3 Medicaid, Medicare, other, and no insurance). We used patient-reported race and ethnicity
4 information and categorized patients into one of five racial/ethnic groups: White, Black, Asian,
5
6 information and categorized patients into one of five racial/ethnic groups: White, Black, Asian,
7
8 Other/Multiracial, and Unknown/Declined. We also identified a subgroup of patients who
9
10 received immunomodulatory medications, including steroids (prednisone or
11
12 methylprednisolone), sarilumab, tocilizumab, anakinra, or colchicine, and included this
13
14 information as a covariate. We identified the presence of the following comorbidities by
15
16 *International Statistical Classification of Disease and Related Health Problems, Tenth Revision*
17
18 *(ICD-10)* coding: cancer, coronary artery disease, hypertension, asthma, chronic obstructive
19
20 pulmonary disease, diabetes, chronic liver disease, chronic kidney disease, and end stage renal
21
22 disease. We calculated the Charlson Comorbidity Index, which is an index that predicts the 10-
23
24 year survival of patients with multiple comorbidities, as a measure of total comorbidity burden.²⁵
25
26 The only covariate with missing data was BMI, and we categorized the BMI group as not obese
27
28 (BMI less than 30kg/m²), obese (BMI greater than or equal to 30kg/m²), and missing BMI.
29
30
31
32

33 We categorized changes in FDA recommendation for hydroxychloroquine, into three
34
35 time periods: 1) pre-FDA approval (March 1-March 27, 2020); 2) FDA approval (March 28-
36
37 April 23, 2020); and 3) FDA warning (April 24-May 11, 2020).
38
39
40
41

42 *Statistical analysis*

43
44 All analyses were performed using version 3.5.2 of the R Programming Language (R
45
46 Project for Statistical Computing, R Foundation, Vienna, Austria). We first performed chi-square
47
48 and 2-sample t-tests to compare patient characteristics treated with hydroxychloroquine to no
49
50 hydroxychloroquine (control).
51
52
53
54
55
56
57
58
59
60

1
2
3 We used propensity-score matching methods, 1:2 for the pre-FDA approval and the FDA
4 warning periods and 1:1 for the FDA approval period, using the smaller group as a reference,
5 within each period and applied the nearest-neighbor method to create a matched control sample.
6
7 The propensity-score matching was performed within each period so that patients admitted
8 within the FDA approval period were not matched to patients in the pre-FDA approval or FDA
9 warning periods, so as not to confound the effect of different FDA recommendations.
10
11
12
13
14
15
16

17 We then took the following approach to conduct the analysis. We first performed logistic
18 regressions to compare the propensity score-matched hydroxychloroquine group to the control
19 group. For a time-to-event analysis, we used the Kaplan-Meier survival estimate and log-rank
20 test. We examined the Kaplan-Meier survival curves for the treatment group compared to the
21 control group, separated by the different FDA recommendation periods. If a patient was
22 discharged alive without intubation, data was censored at the time of hospital discharge. Then,
23 we used Cox proportional-hazard regression models to estimate the association between the
24 propensity-matched treatment group to the control group with respect to end point free survival
25 time. We used the Schoenfeld residuals to test the proportional hazard assumption in the Cox
26 model.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Results**

44 *Characteristics of the cohort*

45
46 From a cohort of 10,009 patients, 3,270 (32.7%) were treated with hydroxychloroquine,
47 2,640 (26.4%) with neither hydroxychloroquine nor azithromycin, 1,289 (12.9%) with
48 azithromycin only, and 2,810 (28.1%) with the combination hydroxychloroquine and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 azithromycin. There were differences in the number of patients treated with or without
4
5 hydroxychloroquine and/or azithromycin by admission period (Figure 1).
6

7
8 We found significant differences in the use of hydroxychloroquine and patient
9
10 characteristics based on changes to FDA recommendation. Number and percentages of patients
11
12 treated with hydroxychloroquine were 192/2202 (8.7%) pre-FDA approval, 2902/6741 (43.0%)
13
14 during FDA approval, and 176/1066 (16.5%) during the FDA warning period (p-value<0.001).
15
16 There was a significant increase in number of patients during the FDA approval period (March
17
18 28-April 23). During the pre-FDA approval period, there were 2,202 patients admitted with
19
20 COVID-19 infection, but in the following periods, the number of patients admitted with COVID-
21
22 19 infections was 6,741 (FDA approval period) and 1,066 (FDA warning period). Throughout
23
24 the study, and independent of FDA periods, there were differences in sociodemographic and
25
26 clinical characteristics between the treatment group compared to the control group (Table 1).
27
28 Higher percentage of patients who were younger (36.8% vs 32.5% were less than 60 years old),
29
30 male (59.9% vs 53.4%), and had commercial insurance (31.0% vs 24.2%) were treated with
31
32 hydroxychloroquine (p-values<0.001). Presence of comorbidity was associated with
33
34 hydroxychloroquine use (all p-values<0.05), except for asthma and diabetes, and chronic kidney
35
36 disease.
37
38
39
40
41

42 Hydroxychloroquine groups (13.4%) had higher rates of intubation compared to the
43
44 control group (7.0%) (p-value<0.001). Inpatient mortality was 20.2% for hydroxychloroquine
45
46 versus 18.3% for no hydroxychloroquine treatment (p-value=0.01). A significantly higher
47
48 percentage of patients treated with hydroxychloroquine (23.4%) reached the composite outcome
49
50 compared to the control group (20.4%) (p-value=0.007). A higher percentage of patients on
51
52
53
54
55
56
57
58
59
60

1
2
3 hydroxychloroquine (52.8%) were treated concurrently with immunomodulatory medications
4
5 compared to the control group (24.7%) (p-value<0.001).
6

7
8 After propensity-score matching within each time period, sociodemographic
9
10 characteristics and comorbidity were similar between hydroxychloroquine and no
11
12 hydroxychloroquine group (Table 2). There were 576 patients in the pre-FDA approval period,
13
14 2812 patients in the FDA approval period, and 528 FDA warning period. There was a higher
15
16 composite outcome among patients treated with hydroxychloroquine (25.5%) compared to no
17
18 hydroxychloroquine (17.2%) during the pre-FDA approval period (p-value=0.03) but no
19
20 difference in the number of composite outcomes between hydroxychloroquine and no
21
22 hydroxychloroquine groups in the FDA-approval period (25.5%, vs 22.6% p=0.08) or the FDA
23
24 warning period (21.0 vs 15.1% %, p=0.11) (Table 3). In the univariate analysis,
25
26 hydroxychloroquine use was associated with increased odds of the composite outcome during the
27
28 pre-FDA approval period (OR=1.65 [1.09-2.51]) but there was no association during the FDA
29
30 approval (OR=1.17 [0.99-1.39]) as well as the FDA warning period (OR=1.50 [0.94-2.39]).
31
32
33
34
35
36
37

38 *Time-to event analysis*

39
40 Figure 2 shows the Kaplan-Meier curves of freedom from the composite end point of
41
42 intubation and inpatient mortality during the pre-FDA approval period, the FDA approval period,
43
44 or the FDA warning period. The cox proportional-hazard regression models showed
45
46 hydroxychloroquine use was associated with the composite outcome of intubation and inpatient
47
48 mortality during the pre-FDA approval (hazard ratio=1.70 [1.17-2.48]) and the FDA warning
49
50 (hazard ratio=1.53 [1.00-2.34]) period but not during the FDA approval period (hazard
51
52
53
54
55
56
57
58
59
60

1
2
3 ratio=1.03 [0.88-1.20]) (Table 3). The proportional hazards assumption was met in the cox
4
5 regression model.
6
7
8
9
10

11 **Discussion**

12
13
14 In our study, while there were changes in percentage of COVID-19 patients treated with
15 hydroxychloroquine with FDA recommendations, there was also a fluctuation of the number of
16 hospitalized patients with COVID-19 infections during the FDA approval period.
17
18

19 Hydroxychloroquine treatment was associated with increased composite outcome of intubation
20 or death during pre-FDA approval period but not during FDA approval or FDA warning period.
21
22

23 The overall association of hydroxychloroquine treatment among COVID-19 patients in our
24 cohort was similar to previous studies showing no association between the treatment and primary
25 end point of intubation or death.^{13,14}
26
27

28 Although not captured in our study, hospitals during the FDA approval period had to
29 manage sudden increases in critically ill patients. As hospitals were reaching their maximum
30 capacity, coordinated efforts were made to ensure that there were adequate ventilators for
31 patients with pulmonary complications, goals of care discussions for patients with poor
32 prognosis, and an increase in ambulatory management to ensure medical care for all patients.²⁶⁻²⁸
33
34

35 Therefore, patients who were admitted during this period may have had more severe disease,
36 including hypoxia, requiring ventilators. This hypothesis is also consistent with the higher
37 proportions of patients experiencing the composite outcome during this period. There was also
38 an increased use of immunomodulators, which were more often used for patients with more
39 complications, including acute respiratory distress syndrome, acute kidney injury, thrombosis,
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 etc.^{1,29,30} Therefore, regardless of whether they were being treated with hydroxychloroquine or
4
5 not, patients admitted during the FDA approval period had overall worse outcomes compared to
6
7 patients admitted during other periods. Because of such differences in patient disease severity
8
9 and hospital settings, we used propensity-score matching of patients within each period so that
10
11 the patients treated in the pre-FDA approval or FDA warning periods were not matched with
12
13 patients treated in the FDA approval period.
14
15

16
17 The lack of efficacy of hydroxychloroquine could be attributed to the severity of disease
18
19 among patients receiving medication. The hypothesized mechanism of action of
20
21 hydroxychloroquine is that it prevents the virus from entering cells and blocks viral replication.⁶⁻
22
23 ⁸ These patients were hospitalized because of a severe course of disease, and therefore it is likely
24
25 that viral replication was already high when hydroxychloroquine was administered. This may be
26
27 particularly true for patients who were hospitalized during the FDA approved period because
28
29 hospitals had a high number of COVID-19 patients requiring inpatient care. Also,
30
31 hydroxychloroquine may have been administered to more severely ill patients and subsequently
32
33 was associated with higher risk of intubation and/or inpatient mortality. We addressed this by
34
35 propensity-score matching patients treated with hydroxychloroquine to no hydroxychloroquine.
36
37 Of note, higher doses of hydroxychloroquine have been associated with adverse intermediate
38
39 outcomes, including QTc prolongation, in another study.³¹
40
41
42
43

44
45 This study has several limitations. Due to the observational study design, this study does
46
47 not establish causal relationships between medication treatment and outcomes. Also, this study is
48
49 limited to the inpatient setting, therefore the study findings are not generalizable to outpatient or
50
51 community settings. Though we did attempt to adjust for covariates, it is possible that the
52
53 severity of illness and precise timing of treatment also may have influenced the association of
54
55
56
57
58
59
60

1
2
3 these medications with the outcome. There might be a subset of patients who were taking
4 hydroxychloroquine prescribed by their ambulatory providers prior to their hospitalization. It is
5 possible that some patients in the no hydroxychloroquine group were taking the medications or
6 already had completed their 5-day course prior to hospitalization. There was a subset of patients
7 in the control group who were treated with hydroxychloroquine or azithromycin after 48 hours
8 because of their disease progression. The changes in the FDA recommendations probably also
9 caused some patients admitted during the pre-FDA approval period to be treated with
10 hydroxychloroquine during their prolonged hospitalizations. This could result in bias toward the
11 null, that is, erroneously concluding no difference between hydroxychloroquine and control
12 (Type II error). The strength of this study, however, is the inclusion of a large, diverse
13 population, including racial and ethnic minorities, extending the generalizability of our study.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Regardless of FDA's recommendation for the drug, we did not observe any beneficial
29 association of hydroxychloroquine use throughout the study period. In addition to changes in the
30 FDA recommendation, this study addresses changes in case mix due to changes in number of
31 COVID-19 patients being hospitalized. This study further confirms that hydroxychloroquine
32 does not alter the clinical course among patients with COVID-19 infections in the inpatient
33 setting where patients have more severe diseases. Additionally, recent evidence suggests that
34 hydroxychloroquine treatment does not alter clinical outcomes among patients with milder
35 symptoms and is not effective as pharmacologic prophylaxis.^{32,33} On June 15, 2020, the FDA
36 revoked the Emergency Use Authorization for hydroxychloroquine in the treatment of COVID-
37 19 infection and this will further decrease the number of COVID-19 patients being treated with
38 hydroxychloroquine.³⁴ These study results should not be used as guidance on whether or not to
39 treat COVID-19 patients with or without hydroxychloroquine due to its observational design.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data Availability Statement

The data that support the findings of this study are available on request from COVID19@northwell.edu. The data are not publicly available due to restrictions as it could compromise the privacy of research participants.

Conflict of Interest Disclosures

The authors report no real or apparent conflicts of interest.

Funding/Support

This work was supported by grants R24AG064191 from the National Institute on Aging of the National Institutes of Health and R01LM012836 from the National Library of Medicine of the National Institutes of Health.

Role of the Funder/Sponsor

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this paper are those of the authors and do not represent the views of the National Institutes of Health, the United States Department of Health and Human Services, or any other government entity.

Patient and Public Involvement

1
2
3 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
4 plans of our research.
5
6
7
8
9

10 **Figures**

11
12 Figure 1. Number of COVID-19 patients treated with different medications
13

14 Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or
15 inpatient mortality by different time period
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020.
3. Angeli F, Bachetti T, Maugeri Study G. Temporal changes in co-morbidities and mortality in patients hospitalized for COVID-19 in Italy. *Eur J Intern Med.* 2020.
4. Horwitz LI, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. *J Hosp Med.* 2020.
5. The Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Published 2020. Accessed June 10, 2020.
6. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020.
7. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-271.
8. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J.* 2005;2:69.
9. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* 2020;6:16.
10. Andreani J, Le Bideau M, Dufloy I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020;145:104228.
11. Grassin-Delyle S, Salvator H, Brollo M, et al. Chloroquine inhibits the release of inflammatory cytokines by human lung explants. *Clin Infect Dis.* 2020.
12. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol.* 2020;16(3):155-166.
13. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020.
14. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA.* 2020.
15. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ.* 2020;369:m1849.
16. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect.* 2020;50(4):384.
17. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv.* 2020.
18. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus

- disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2020.
19. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020:105949.
 20. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends.* 2020;14(1):72-73.
 21. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv.* 2020.
 22. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis.* 2020;97:396-403.
 23. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA.* 2020.
 24. Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. U.S. Food & Drug Administration <https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use>. Accessed May 15, 2020.
 25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
 26. Curtis JR, Kross EK, Stapleton RD. The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019 (COVID-19). *JAMA.* 2020.
 27. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *BMJ.* 2020;368:m1182.
 28. White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic. *JAMA.* 2020.
 29. Hirsch JS, Ng JH, Ross DW, et al. Acute Kidney Injury in Patients Hospitalized with Covid-19. *Kidney Int.* 2020.
 30. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood.* 2020;135(23):2033-2040.
 31. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open.* 2020;3(4):e208857.
 32. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Intern Med.* 2020.
 33. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med.* 2020;383(6):517-525.

- 1
2
3 34. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for
4 Chloroquine and Hydroxychloroquine. U.S. Foods and Drug Administration.
5 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
6 [fda-revokes-emergency-use-authorization-chloroquine-and](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and). Published June 15, 2020.
7 Accessed June 20, 2020.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Patient characteristics before propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	All (n=10,009)	HCQ (n=3,270)	No HCQ (n=2,640)	P-value*
Sociodemographic characteristics				
Age at admission, mean (SD)	64.99 (16.35)	64.29 (15.58)	66.87 (17.73)	<0.001
Age group				<0.001
18-49	1747 (17.5)	558 (17.1)	434 (16.4)	
50-59	1863 (18.6)	645 (19.7)	425 (16.1)	
60-69	2277 (22.7)	816 (25.0)	530 (20.1)	
70-79	2046 (20.4)	671 (20.5)	518 (19.6)	
80+	2076 (20.7)	580 (17.7)	733 (27.8)	
Male	5847 (58.4)	1959 (59.9)	1411 (53.4)	<0.001
Race				<0.001
White	3923 (39.2)	1151 (35.2)	1182 (44.8)	
Black	2104 (21.0)	632 (19.3)	581 (22.0)	
Asian	849 (8.5)	327 (10.0)	236 (8.9)	
Other/Multiracial	2648 (26.5)	958 (29.3)	540 (20.5)	
Unknown	485 (4.8)	202 (6.2)	101 (3.8)	
Health insurance				<0.001
Commercial	2947 (29.4)	1013 (31.0)	638 (24.2)	
Medicaid	2041 (20.4)	712 (21.8)	488 (18.5)	
Medicare	4754 (47.5)	1431 (43.8)	1453 (55.0)	
Other	133 (1.3)	46 (1.4)	45 (1.7)	
No insurance	134 (1.3)	68 (2.1)	16 (0.6)	
Comorbidity				
Cancer	832 (8.3)	238 (7.3)	278 (10.5)	<0.001
Coronary artery disease	1339 (13.4)	399 (12.2)	429 (16.2)	<0.001
Hypertension	6073 (60.7)	1973 (60.3)	1673 (63.4)	0.02
Peripheral artery/vascular disease	282 (2.8)	81 (2.5)	100 (3.8)	0.005
Asthma	842 (8.4)	271 (8.3)	198 (7.5)	0.29
Chronic obstructive pulmonary disease	639 (6.4)	168 (5.1)	174 (6.6)	0.02
Diabetes	3624 (36.2)	1233 (37.7)	945 (35.8)	0.14
Chronic liver disease	298 (3.0)	74 (2.3)	110 (4.2)	<0.001
Chronic kidney disease	507 (5.1)	155 (4.7)	152 (5.8)	0.09
End stage renal disease	461 (4.6)	144 (4.4)	168 (6.4)	0.001
Charlson Comorbidity Index, mean SD	4.89 (3.58)	4.56 (3.38)	5.74 (3.77)	<0.001
Obesity				<0.001
Obese	2810 (28.1)	1001 (30.6)	570 (21.6)	
Not obese	4632 (46.3)	1483 (45.4)	1296 (49.1)	
Missing BMI	2567 (25.6)	786 (24.0)	774 (29.3)	
BMI, mean (SD)	29.23 (7.06)	29.66 (7.04)	28.13 (7.14)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical outcomes

Admission week				<0.001
Pre-FDA approval	2202 (22.0)	192 (5.9)	496 (18.8)	
FDA approval	6741 (67.3)	2902 (88.7)	1406 (53.3)	
FDA warning	1066 (10.7)	176 (5.4)	738 (28.0)	
Length of stay, mean (SD)	9.51 (9.60)	9.56 (9.14)	8.80 (9.27)	0.001
Immunomodulator use	4183 (41.8)	1727 (52.8)	651 (24.7)	<0.001
ICU stay	1985 (19.8)	583 (17.8)	426 (16.1)	0.09
Mechanical ventilation	1314 (13.1)	437 (13.4)	186 (7.0)	<0.001
Inpatient mortality	1983 (19.8)	660 (20.2)	482 (18.3)	0.01
Composite Outcome	2413 (24.1)	764 (23.4)	538 (20.4)	0.007

* Comparing hydroxychloroquine group to no treatment group

Table 2. Patient characteristics after propensity-score matching, number (percentage) for categorical variable and mean (standard deviation) for continuous variable

	Pre-FDA approval			FDA approval			FDA warning		
	HCQ (n=192)	No HCQ (n=384)	SMD	HCQ (n=1406)	No HCQ (n=1406)	SMD	HCQ (n=176)	No HCQ (n=352)	SMD
Sociodemographic characteristics									
Age at admission, mean (SD)	61.1 (15.8)	62.8 (17.2)	0.101	67.8 (15.8)	67.3 (17.6)	0.03	66.2 (16.2)	66.3 (17.6)	0.007
Male	109 (56.8)	218 (56.8)	<0.001	740 (52.6)	765 (54.4)	0.036	92 (52.3)	194 (55.1)	0.057
Race			0.134			0.013			0.05
White	91 (47.4)	180 (46.9)		610 (43.4)	612 (43.5)		65 (36.9)	136 (38.6)	
Black	35 (18.2)	86 (22.4)		306 (21.8)	302 (21.5)		37 (21.0)	69 (19.6)	
Asian	17 (8.9)	37 (9.6)		143 (10.2)	143 (10.2)		12 (6.8)	25 (7.1)	
Other/Multiracial	44 (22.9)	72 (18.8)		297 (21.1)	296 (21.1)		53 (30.1)	106 (30.1)	
Unknown	5 (2.6)	9 (2.3)		50 (3.6)	53 (3.8)		9 (5.1)	16 (4.5)	
Health insurance			0.257			0.039			0.036
Commercial	91 (47.4)	134 (34.9)		306 (21.8)	321 (22.8)		44 (25.0)	92 (26.1)	
Medicaid	30 (15.6)	72 (18.8)		246 (17.5)	249 (17.7)		31 (17.6)	62 (17.6)	
Medicare	71 (37.0)	178 (46.4)		819 (58.3)	805 (57.3)		92 (52.3)	182 (51.7)	
Other	0 (0.0)	0 (0.0)		27 (1.9)	22 (1.6)		6 (3.4)	11 (3.1)	
No insurance	0 (0.0)	0 (0.0)		8 (0.6)	9 (0.6)		3 (1.7)	5 (1.4)	
Comorbidity									
Cancer	10 (5.2)	25 (6.5)	0.055	134 (9.5)	151 (10.7)	0.04	16 (9.1)	30 (8.5)	0.02
Coronary artery disease	23 (12.0)	56 (14.6)	0.077	218 (15.5)	222 (15.8)	0.008	27 (15.3)	53 (15.1)	0.008
Hypertension	109 (56.8)	237 (61.7)	0.101	915 (65.1)	884 (62.9)	0.046	107 (60.8)	205 (58.2)	0.052
Peripheral artery/vascular disease	7 (3.6)	13 (3.4)	0.014	48 (3.4)	42 (3.0)	0.024	6 (3.4)	6 (1.7)	0.108
Asthma	24 (12.5)	35 (9.1)	0.109	88 (6.3)	100 (7.1)	0.034	17 (9.7)	32 (9.1)	0.019
Chronic obstructive pulmonary disease	9 (4.7)	23 (6.0)	0.058	83 (5.9)	87 (6.2)	0.012	14 (8.0)	29 (8.2)	0.01
Diabetes	70 (36.5)	138 (35.9)	0.011	515 (36.6)	508 (36.1)	0.01	68 (38.6)	131 (37.2)	0.029
Chronic liver disease	7 (3.6)	15 (3.9)	0.014	47 (3.3)	56 (4.0)	0.034	7 (4.0)	19 (5.4)	0.067
Chronic kidney disease	11 (5.7)	25 (6.5)	0.033	84 (6.0)	80 (5.7)	0.012	8 (4.5)	17 (4.8)	0.013

1										
2										
3	End stage renal disease	12 (6.2)	27 (7.0)	0.031	99 (7.0)	101 (7.2)	0.006	4 (2.3)	8 (2.3)	<0.001
4	Charlson Comorbidity Index, mean									
5	SD	4.23 (3.19)	4.73 (3.32)	0.152	5.72 (3.75)	5.69 (3.73)	0.008	5.03 (3.23)	5.01 (3.42)	0.005
6	Obesity			0.198			0.022			0.027
7										
8	Obese	76 (39.6)	116 (30.2)		289 (20.6)	292 (20.8)		50 (28.4)	98 (27.8)	
9	Not obese	69 (35.9)	160 (41.7)		678 (48.2)	663 (47.2)		84 (47.7)	166 (47.2)	
10	Missing BMI	47 (24.5)	108 (28.1)		439 (31.2)	451 (32.1)		42 (23.9)	88 (25.0)	
11	Clinical outcomes									
12										
13	Length of stay, mean (SD)	10.88 (11.20)	10.48 (11.79)	0.035	9.29 (8.66)	7.75 (7.82)	0.187	8.67 (7.55)	8.28 (7.40)	0.053
14	Mechanical ventilation	33 (17.2)	29 (7.6)	0.296	168 (11.9)	85 (6.0)	0.207	26 (14.8)	25 (7.1)	0.248
15	Inpatient mortality	31 (16.1)	55 (14.3)	0.272	318 (22.6)	294 (20.9)	0.086	32 (18.2)	46 (13.1)	0.079
16	Composite Outcome	49 (25.5)	66 (17.2)	0.204	359 (25.5)	318 (22.6)	0.068	37 (21.0)	53 (15.1)	0.156

* Comparing hydroxychloroquine group to no treatment group

SMD=Standardized mean difference

Table 3. Association between hydroxychloroquine use and the composite end point in the crude analysis and propensity-score matched analysis

Analysis	Results	P-value*
Composite outcome among patients at risk, n (%)		
Before propensity score matching		
All periods		
Overall	2080/10009 (23.9)	-
Hydroxychloroquine	764/3270 (23.4)	0.007
No HCQ	538/2640 (20.4)	
After propensity score matching		
Pre-FDA approval		
Hydroxychloroquine	49/192 (25.5)	0.03
No HCQ	66/384 (17.2)	
FDA approval		
Hydroxychloroquine	359/1406 (25.5)	0.08
No HCQ	318/1406 (22.6)	
FDA warning		
Hydroxychloroquine	37/176 (21.0)	0.11
No HCQ	53/352 (15.1)	
Univariate analysis - odds ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.65 [1.09-2.51]	0.02
FDA approval (reference: no HCQ)	1.17 [0.99-1.39]	0.07
FDA warning (reference: no HCQ)	1.50 [0.94-2.39]	0.09
Propensity-score matched analyses-hazard ratio [95% confidence interval]*		
Pre-FDA approval (reference: no HCQ)	1.70 [1.17-2.48]	0.005
FDA approval (reference: no HCQ)	1.03 [0.88-1.20]	0.72
FDA warning (reference: no HCQ)	1.53 [1.00-2.34]	0.05

* Comparing hydroxychloroquine group to no treatment group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47





Figure 1. Trends in COVID-19 patients treated with different medications

Figure 2. Kaplan-Meier curve showing freedom from composite end point of intubation or inpatient mortality by different time period



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 and 3
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 5 and 6
Objectives	3	State specific objectives, including any prespecified hypotheses Page 6 lines 13-16
Methods		
Study design	4	Present key elements of study design early in the paper Page 6 line 20
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 6 lines 19-Page 7 line 3, Page 7 lines 11-14, Page 8 lines 19
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants Page 7 lines 10-22
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 8 lines 4-Page 9 line 16
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 7 lines 5- 8
Bias	9	Describe any efforts to address potential sources of bias Page 10 lines 1-6
Study size	10	Explain how the study size was arrived at Page 7 lines 10-22
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 8 line 21- Page 9 line 13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 9 line 18-Page 10 line 16 (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed Page 9 lines 12-13 (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses Page 8 lines 18-19
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 7 lines 11-15, line 22 (b) Give reasons for non-participation at each stage

		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 10 line 20-page 12 line 14
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers of outcome events or summary measures Page 12 lines 6-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 12 lines 6-Page 13 line 2
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives Page 13 lines 5-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14 line 18-Page 15 line 9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 14 lines 6-17
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 15 lines 9-10
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 16 lines 9-12

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.